¡@
¡@
®ð³Ý¤§©I§l¹D«¼Ò²Õ¤Æ
¥Õ¤T²m¯ÀªýÂ_¾¯
Ä_Ä_¡u«¦¡v¤£°±~®ð³Ýªº©~®a·ÓÅ@
¹ï¨àµ£®ð³Ýªº¥t¤@ºØ»{ÃÑ
¨àµ£®ð³ÝªvÀø¤§¹êÃÒÂå¾Ç
¦p¦ó¥¿½T¦YÃÄ
¥®¨à²Ó¤ä®ðºÞª¢¤ÎªÍª¢
Baby¥´©I¬O®ð³Ýªº«e¥ü¡H
²§¦ì©Ê¥Ö½§ª¢
²¾°£«Ç¤ºªº¹L±Óì
®ð³ÝªvÀøªº²{ª¬»PÁͶÕ
^󻓩]
AAAAI 60¶g¦~¼y---¤¦¦ò¬ö¦æ
¡@
Survey of the
Clinical Practice of Physicians in
the Management of Asthma in Taiwan
Allergens and Allergic
Diseases in Children
¡@
Survey of
asthma care in Taiwan: a comparison of asthma
specialists and general practitioners
¡@
|
||||||
ªø©°¨àµ£Âå°| ¨àµ£¹L±Ó®ð³Ý·Àã¬ì ¸°ê°¶Âå®v
²³©Ò¶gª¾¡A¨àµ£®ð³Ýªº²±¦æ²v»P¤éѼW¡A§xÂZµÛ³\¦h¤pªB¤Í¤Î®aªø¡AµM¦Ó¹ï®ð³Ýªº»{ÃѤιï¤pªB¤Íªº·ÓÅU«o¥¼¯à¦³§ó¥¿½Tªº»{ª¾¡A¤Ï¦Ó³y¦¨·ÓÅU¤Wªºª¼ÂI¡A¤]®ø¯Ó³\¦hª÷¿ú»Pºë¤O¡C ³\¦h®aªø¤@Å¥Âå®v¶EÂ_¦Û¤vªº¤p«Ä±w¦³®ð³Ý®É«K¦p¦P¿©±w¤Fµ´¯g¯ë¤£¸T´d±q¤¤¨Ó¥B¤£ª¾©Ò±¹¡C®ð³Ý¥»½è¤W¬O©I§l¹DªººC©Êµoª¢¤ÏÀ³¡AµM¦ÓÁ{§É¤W¨àµ£®ð³Ý¨Ã«D¤£ªv¤§¯g¡Aµ´¤j³¡¤À¬O¥iªv·Uªº¡A«nªº¬On¦³@¤ß¥B¿í´`Âå®vªº³B¤è»P«Øij¡A²¦³ºªvÀø®É¶¡ªºªøµu¦]¤H¦Ó²§¡A¦ý¨M¤£¹³·P«_¯ë¥un3¦Ü5¤Ñ«K¥i´_ì¡C¤×¨ä§ó»Ý¦´ÁªvÀø¡A¥H´î¤Öµo§@ªº¾÷·|¡C¥Ñ©ó®ð³Ýµo§@®É¤£¶È®aªø¼~¤ß¡A¦bªÍ³¡²Õ´§ó¦]µoª¢¦Ó«á·|³y¦¨¤£¥i°fªºÅÖºû¤Æ¡AY¤ÏÂЪºµo§@¡AÅÖºû¤Æµ{«×«h·|§ó¼F®`§ó¼sªx¡A±N¨Óªø¤j§ó¥i¯à¼vÅTªÍ³¡ªºª¬ºA¤Î¥\¯à¡A¦]¦¹¤Î¦ªvÀø¬O·¥«nªº¡C¥Ø«e¥Î¨Ó¹w¨¾«O¾iªºÃĪ«¬O§l¤J©ÊÃĪ«¡A¥]¬A§l¤J©ÊÃþ©T¾J¤Î«DÃþ©T¾Jµ¥¡AµM¦Ó¥un¤@Å¥¨ìÃþ©T¾J®aªø«K°hÁפTªÙ¡A²`©È¼vÅTµo¨|©Î¦³¥ô¦óªº°Æ§@¥Î¦Ó¤£´±µ¹¤pªB¤Í¨Ï¥Î¡AµM¦ÓY¤£¥Î«o®e©ö¨Ï®ð³Ý¤ÏÂеo§@¡A¹ï¨àµ£±o¥Í²z¤Î¤ß²z¼vÅT§ó¤j¡C¦b¦¹±j½Õ§l¤J©ÊÃĪ«¬O¥Ø«eªvÀø®ð³Ýªº¥D¬y¡A¨Ã«Dn¨Ì¿à¨ä¤@½ú¤l¡A¦Ó¬Oµø¤pªB¤Íªº§ïµ½µ{«×»PÂå®v°Q½×¨Ó½Õ¾ã¨ä¨Ï¥Î¾¯¶q¤ÎÀW²v¡Aª¬ªpéw«á«hº¥º¥´î¶q¦Ó°±ÃÄ¡CÅv¿Å¨ä§Q®`±o¥¢¡Aµ´¹ï§Q¦h©ó¹ú¡A¤Á¤Å¦]¼O¼o¹¡C ®a¤¤Y¦³®ð³Ý¨à¥Í¬¡¤WÃø§K¨ü¼vÅT¡A¥Xªù¥þ°ÆªZ¸ËÀ¹¤f¸n¡A¤S¬O¤£¯à¹B°Ê¡A¤S¬O¤£¯à¦YÁ¦±ø¡A¤£¯à¦Y¦B¡K¡A¦b¤pªB¤Íªº¦Õ¤¤¥Rº¡¤F§i»|¦¡ªº¸T¥O¡AÅý¤@Áû·Q¸ªº¤ßÀH®É¨ü¨ì¸TÀD¡A¦Û¤v¤]³Q¼ÐÅÒ¬°¡u¹L±Ó¨à¡v©Î¡u®ð³Ý¨à¡v¡C¨ä¹ên¤pªB¤Í¤£¶]¤£¸õ¬O¤£¤Ó¥i¯àªº¡A¾A«×ªº¹B°Ê¬Oȱo¹ªÀyªº¡A¥®É¨Ï¥Î«O¾iªº§l¤J©ÊÃĪ«¤]¥i´î¤Ö¹B°Ê»¤µo®ð³Ýªº¥i¯à¡A¦P®É¥R¤À¤F¸ÑY¦]¹B°Ê»¤µo³Ý»ïªº³B¸m¤è¦¡¡A´NÅý¤pªB¤Íµo´§¨ä¤Ñ©Ê¡A¤]¤£¦Ü¤ß²z¥Ã»·»X¤W¤@¼h³±Åµ¡C¦Ü©ó¦]¹ª«¤Þ°_®ð³Ýªº¯gª¬¨Ã¤£±`¨£¡A¤]¨Ã«D¨CÓ®ð³Ý¤pªB¤Í¦Y¦B«K·|®ð³Ý©Î«y¹Â¡A¦]¦¹¥i¹Á¸Õ¦Y¤@ÂI¡AY©úÅ㦳¯gª¬«hÀ³ÁקK¡AYµL¯gª¬«h¦b®aªøªººÊ·þ¤U¦ó§«Åý´ç¨Ç¦Û¥Ñ¡C¹ï©ó¸ûÀ´¨Æªº¤p«Ä¡A·íµM¤]¤£À³¦Û»{¬°¦³®ð³Ý¦ÓÁŧK³\¦h¾Ç®Õªº¬¡°Ê©Î¥H¦¹¬°ÂǤf¦Ó°kÁ×À³ºÉªº¸q°È¡A¦Ó¦b¦P¾«¶¡¾AÀ³¤£¨}¡CÂå®v¡A®aªø¡A¦Ñ®v¤Î¤pªB¤Í¦h¤èªº·¾³q¡A¤~¤£·|¼vÅT¨ä¤ß²z¼h±ªºµo®i¡C ´CÅé¸ê°T¤é¯qµo¹F¡Aºô»Úºô¸ô¤]µL»·¥±©¡¡A¥R¥¸µÛ¦UºØ¦ü¬O¦Ó«D©ÎÂ_³¹¨ú¸qªºÂåÃĸê°T©Î¼s§i¡A®aªø·R¨à¤ß¤Á¤]ÂǥѦUºØ¸ê°TºÞ¹D¹M³X¦WÂå¡A´M¨D¦W¶QÃħ÷°¾¤è¡A¥u¨D¯àªv·U®ð³Ý¡C¦b±µ¦¬¨ì¦UºØ¦³Ãö¹L±Ó®ð³Ýªº¸ê°T®É¡A®aªø»Ýª`·N¥B¦Û§Ú¬Ù«äªº¬O³o¨ÇÂåÃÄ·sª¾¬O§_¬°ÃÄ«~¼s§i©Î¸Ø¤j¤£¹ê?Àø®Ä¦³µL¬ì¾Ç®Ú¾Ú?¬O§_¤w¥Î©ó¤HÃþÁÙ¬O¤´¦b°Êª«¹êÅ綥¬q?¦]¬°°Êª«¹êÅ窺¦¨¥\¨Ã¤£¥Nªí¾A¥Î©ó¤HÅé¤W¡A´Nºâ¹ï¤HÅ馳®Ä¤]¨Ã«D¾A¥Î¨CÓ¦~ÄÖ¼h©Î¨CÓÓÅé¡C¹ï©ó©ÒÀò±oªº¸ê°TÀ³»P±M¬ìÂå®v¦A§@¶i¤@¨Bªº°Q½×»P¤F¸Ñ¡A¦Ó¤£¬O³d©ÇÂå®v¤£¥Î·sÃĩηsªºªvÀø¤è¦¡¡C ¥H¤W´XÂI¹ïÃĪ«¨Ï¥Îªº»{ª¾¡A¹ï®ð³Ý¤pªB¤Íªº¤ß²z¼h±¡A¤Î¹ï´CÅ骺¼f·VºA«×§Æ±æ»P®aªø¦@«j¡C ¡@ ¡@ |
||||||
ªø©°¨àµ£Âå°| ¨àµ£¹L±Ó®ð³Ý·Àã¬ì¥DªvÂå®v ¸°ê°¶
¯f¨Ò ³o¬O¤@Ó5·³ªº¨k«Ä¥Ñ¶ý¶ý±a¨Ó¨à¬ì«æ¶E¡A¥D¶D¨ä«y¹Â¤w5¤Ñ¦ý¤@¤Ñ¥H¨Ó«h©I§l§xÃø¡C¯f¤H³Ìªñ5¤Ñ«K¶}©l«y¹Â¡A±ß¤W¤]¦]«y¹Â¦ÓµLªk¦¨¯v¡A®É±`«y¿ô¡A¦¤W°_§É§ó¬O«yªº¼F®`¡A³Ìªñ¤@¤Ñ¬Æ¦Ü«y¨ì³sÁ¿¸Ü³£Â_Â_ÄòÄò¡A¨«´X¨B¸ô³£n¥ð®§¡C®Ú¾Ú¶ý¶ýªº³¯z¡A¯f¤H¥®É«K«Ü®e©ö·P«_¡A¤Ñ®ð¤@ÅÜ´N«y¹Â¬y»ó¤ô¡A·P«_¤]³£n¦Y«Ü¤[ªºÃĤ~·|¦n¡A·P«_ÄY«®ÉÁÙ·|¦³¡y«¦«¦¡zªº³Ý»ïÁn¡F¥®É·|¦]¹B°Ê©Î¿E¯P°Ê§@¦Ó«y¹Â¡C¥t¥~¦¤W°_§É´N³sÄò¥´¼QÀ¡¡A²´·ú¤]±`Äo±`´|¡C²z¾ÇÀˬd¥i¬Ý¨ì¨k«Ä¦]¨Ï¥Î»²§U©Ê¦Ù¦×¦³¨Ç¯Ý°©¤W¥W³´¡AÅ¥¶E¥iÅ¥¨ì¨â°¼ªÍ³¡©úÅ㪺³Ý»ïÁn¡A©I§l³t²v¬ù¨C¤ÀÄÁ40¦¸¡A¤ß¸õ¬ù¨C¤ÀÄÁ110¦¸¡A¨S¦³µo¿N¡A¨ä¾lªº²z¾ÇÀˬd¤jP¥¿±`¡Cªì¨B¶EÂ_¬°«æ©Ê®ð³Ýµo§@¡A¦]¦¹°¨¤W©I¥s©I§lªvÀø¬ìÅ@¤hµ¹¤©Bricanyl inhalation¡C©I§lªvÀø¬ìÅ@¤h°Ý¬OnAtrovent¥[BricanylÁÙ¬O¥unBricaynl ´N¦n¡HÅ@¤h¤p©j¤]°Ýn¤£nª`®gÂIºwµ¹Aminophylline¡H¦Ò¼{«áÁÙ¬O¨M©w¥uµ¹Bricanyl inhalation¡C¯f¤H¹ïBricanyl §l¤Jªº¤ÏÀ³´¶³q¡A®Ú¾Ú¾Çªø«ü¾É¡A¹j20¤ÀÄÁ¦A§l¤@¦¸¡A§l§¹2¦¸«á¯f¤H±¡ªp§ïµ½¡A¦]¦¹¶}¥ßPrednisolone¡ABerotec¤fªAÃĪ«¦^®a¡A¨ÃÅñ¨ä¦^ªù¶Eªø´Á°lÂܪvÀø¡C¯f¤H¦^ªù¶E«á®Ú¾Ú¯f¤Hªº¯f¥v¤ÎÄY«µ{«×¶}©l±µ¨ü§l¤J«¬Ãþ©T¾JªºªvÀø¡A¨Ã±Ð¾É¨ä¥¿½Tªº¨Ï¥Î¤è¦¡¡C§ÚÌÂǥѳoÓ¯f¨Òªº¤Þ¾É§Q¥Î¹êÃÒÂå¾ÇªºÆ[ÂI¨Ó¶i¤@¨B¤F¸Ñ¦b®ð³ÝªvÀø¤W¤@¨Çȱo°Q½×ªº¦a¤è¡A¼fµø¥®É¦]´`ªº³B¸m¤è¦¡¬O§_±o·í¡C¥H¤U¤]±N¤À¦¨«æ©Ê³B²z¤ÎºC©ÊªvÀø¤À§OÄÄz¡C ªvÀø®ð³Ý¦³³\¦h¦@³qªº·Ç«h¡AµM¦Ó³o¨Ç·Ç«hªº²£¥Í¤]³£»Ýn¦³¹êÅçÃÒ¾Ú¨Ó¤ä«ù¡C³o¨ÇÃÒ¾Ú¤jP¥i°µ¥H¤U¤ÀÃþ¡J Level I¡R¦Ü¤Ö¦³¤@Ó¥HÀH¾÷¨ú¼Ë©Ò°µªºÁ{§É¸ÕÅçÀò±oªºÃÒ¾Ú¤ä«ù Level II¡R¦Ü¤Ö¦³¤@Ó¥H¥@¥N©Ê(cohort)©Î¯f¨Ò¹ï·Ó(case-control)ªº¹êÅç¤è¦¡¥B³]pÄYÂÔªºÁ{§É¸ÕÅç©ÒÀò±oªºÃÒ¾Ú¤ä«ù Level III¡R¸g¥Ñ³\¦h±M®a®Ú¾ÚÁ{§É¸gÅç¦@¦P°Q½×¦Ó±o¨Óªºµ²ªG Y¬°ªvÀø«Øij¤S¥i¦A²Ó¤À¬°¥H¤U¤ÀÃþ A. ¦³¥R¤ÀªºÃÒ¾Ú¤ä«ù¨Ã«Øij¦¹¶µ³B¸m B. ¦³¾A·íªºÃÒ¾Ú¤ä«ù¨Ã«Øij¦¹¶µ³B¸m C. µLÃÒ¾Ú¤ä«ù«Øij©Î¤£«Øij¦¹¶µ³B¸m D. ¦³¾A·íªºÃÒ¾Ú¤£¤ä«ù¥B¤£«Øij¦¹¶µ³B¸m E. ¦³¥R¤ÀÃÒ¾Ú¤£¤ä«ù¥B¤£«Øij¦¹¶µ³B¸m
«æ©Ê³B²z µu®Ä«¬§l¤J©Ê¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¡]£]2-agonist¡^¤´¬O¥Ø«e³B²z®ð³Ýµo§@ªº²Ä¤@½u¥ÎÃÄ¡A¤@¯ë§l¤J¼Æ¤ÀÄÁ¤º«K¦³§@¥Î¡A¦P®ÉÃĮĥiºû«ù3¦Ü4¤p®É¥ª¥k¡C¬Û¹ï©ó¤fªA©ÎÀR¯ßª`®gªº³~®|¡A§l¤J©Êªº¤è¦¡¯à¸û¦³®Äªº±NÃĪ«°e¶i®ðºÞ¦Ó¹F¨ìªvÀøªº®ÄªG¡C¦b«æ©Êµo§@®É§l¤Jµu®Ä«¬£]2-agonistÀW²v¶V±K¶°¡A¶V§Ö¹F¨ìªvÀø®ÄªG¡C¥H2²ÕÄY«µ{«×¬Û¦üªº¨àµ£¤ñ¸û¡A¤@²Õ¨C¤@¤p®É§l salbutoml 0.15 mg/kg¦@3¦¸¡A¥t¤@²Õ¤@¶}©lµ¹¤©salbutoml 0.15mg/kg¤@¦¸¡A¤§«á¨C20¤ÀÄÁµ¹0.05mg/kg¦@6¦¸¡A¥HFEV1§@¬°µû¦ô¼Ð·Çµo²{2²Õ¹ï²Ä¤@¾¯§l¤J¦³¬Û¦üªº¤ÏÀ³¡A¦ý¸û±`§lÃĪº¤@²Õ¦b¤@¤p®É¤ºªÍ¥\¯à«ùÄò¶i¨B¡A¥t¤@²Õ«hªÍ¥\¯à¦b§l¤U¤@¾¯«e·|¦³¨Ç³\¤U°¡CÁöµM2²Õ³Ì«áªºFEV1¨Ã¨S¦³®t§O¡A¦ý«æ©Ê´Á¸ûÀWÁc§l¤J£]2-agonist¥i«ùÄòºû«ùªÍ¥\¯àéw¡]Level IA¡^¡C¥t¤@¬ã¨s«h¥Îsalbutoml 0.15 mg/kg¨C20¤ÀÄÁ§l¤J¤@¦¸»Psalbutoml 0.05 mg/kg¨C20¤ÀÄÁ§l¤J¤@¦¸¨Ó¤ñ¸û¡Aµo²{¸û°ª¾¯¶q¦³¸û¦nªº¤ÏÀ³¦ý°£¤F¤â§Ýªº°Æ§@¥Î¸û©úÅã¥~¨ä¾l¨ÃµL°Æ§@¥Î¡A¦]¦¹«æ©Ê´Á¥Î¸û°ª¾¯¶qªº£]2-agonist¥BÀWÁc§l¤J¬O¦³¸û¦nªº®ÄªG¡]Level IA¡^¡C ¯f¤H¦]®ð³Ý¨ì«æ¶E¤@¯ë¨Ï¥Î®ðÃú¦¡¡]nebulizer¡^§ë¤©¤ä®ðºÞÂX±i¾¯¡A¨Ï¥Î¦¹§l¤J¤è¦¡ªº¦n³B¬O²³æ¡A¨Ã¤£»Ýn¯f¤Hªº°t¦X«K¥i§l¤JÃĪ«¡A¦ý¨Æ¹ê¤W¶i¤J®ðºÞªº¾¯¶q½T·¥¤Ö¡A¤j³¡¤ÀªºÃĪ«³£®ö¶O¤F¡C¨Ï¥Î©w¶q¼QÃú¾¯¡]metered dose inhaler¡^¥[¤W§lÃÄ»²§U¿µ¥ç¬O¥t¤@ºØ§l¤Jªº¤è¦¡¡C¥ÑºC©Ê®ð³Ýªº¬ã¨sµo²{¨Ï¥Î©w¶q¼QÃú¾¯¥[¤W§lÃÄ»²§U¿µ¤ñ¨Ï¥Înebulizer¦bªÍ¥\¯à§ïµ½¤è±¦Ü¤Ö¦³¬Û¦P¬Æ¦Ü§ó¦nªº®ÄªG¡]Level IA¡^¡C¥ç¦³¨â¶µ³]pÄY±Kªº¬ã¨s°w¹ï©ó«æ¶E¨Ï¥Înebulizer©Î©w¶q¼QÃú¾¯¥[¤W§lÃÄ»²§U¿µ§ë¤©¤ä®ðºÞÂX±i¾¯µo²{¹ï©ó§ïµ½®ð³Ý¯gª¬¡A´î¤Ö¦í°|¾÷²v¤Î¦y®p©I§l³t²v(peak expiratory flow rate)ªº§ïµ½¨ÃµL®t§O¡A¬Æ¦Ü¨Ï¥Î©w¶q¼QÃú¾¯¥[¤W§lÃÄ»²§U¿µªº¤@²Õªá¸û¤Öªº®É¶¡«K±o¨ì¬Û¦PªºªvÀø¡C¦]¦¹¦b«æ©Êµo§@®É¨Ã¤£¤@©w¥u¯à¥Înebulizerªº¤è¦¡¨Ï¥Î¡A¯à¤è«K¨Ï¥Î©w¶q¼QÃú¾¯¥[¤W§lÃÄ»²§U¿µ¤]¦³¬Û¦P®ÄªG¡C «æ©Êµo§@®É¨Ï¥Î§l¤J©Ê¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¬O¤½»{ªºªvÀø·Ç«h¡A¥[¤J§l¤J©Ê§ÜÁxÆP»s¾¯¥ç¬OÁ{§É¤W±`¥Îªº³B²z¤èªk¡C§l¤J©Ê§ÜÁxÆP»s¾¯¸û§l¤J©Ê¤ä®ðºÞÂX±i¾¯ªº°_©l§@¥Î®É¶¡¸ûºC¡A¦ý§@¥Î®É¶¡¸ûªø¡C¦ý¦X¨Ö¨Ï§l¤J©Ê§ÜÁxÆP»s¾¯¬O§_¦³§ó¦nªºªvÀø®ÄªG¡H¦b¤@¥æ¤e¤ÀªRªº¦^ÅU¤å³¹¤¤´£¨ì§l¤J©Ê¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¥[¤W¤@¾¯ªº§l¤J©Ê§ÜÁxÆP»s¾¯¦b60¤ÀÄÁ«á¥i§ïµ½FEV1¡A¦ý½T¤£·|´î¤Ö¦í°|¾÷²v¡C¦ýY¥[§l¦h¾¯§l¤J©Ê§ÜÁxÆP»s¾¯«h¥i¥H´î¤Ö¦í°|¾÷²v¡C¥t¤@¶µ¬ã¨s¿ï¾Ü¤F480¦ì¦³¤¤««×®ð³Ýªº¨àµ£¡A¹ï©ó««×®ð³Ýªº¨àµ£¥[¤J§l¤J©Ê§ÜÁxÆP»s¾¯2¦¸«á¥i´î¤Ö¦í°|¾÷²v¡C¥t¤@¬ã¨s¤ñ¸û¹êÅç²Õ³sÄò§l¤J©Ê§ÜÁxÆP»s¾¯¥[¤W§l¤J©Ê¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¤T¦¸»P¹ï·Ó²Õ¥u§l¤J¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¤ñ¸ûµo²{¦³¨Ï¥Î§l¤J©Ê§ÜÁxÆP»s¾¯Áö¥¼´î¤Ö¦í°|¾÷²v¦ý¥i¸û¦¥Ñ«æ¶E¥X°|¡]Level IA¡^¡C¥Ñ³\¦h¬ã¨sÃÒ¾ÚÅã¥Ü¹ï©ó««×®ð³Ý(predicted FEV1<55%)¦h¦¸¦X¨Ö¨Ï¥Î§l¤J©Ê§ÜÁxÆP»s¾¯¤Î§l¤J©Ê¤ä®ðºÞÂX±i¾¯©ó¦w¥þµL¸·¡A¥i§ïµ½ªÍ¥\¯à¡A¤]¥i´î¤Ö¦í°|¾÷²v¡C¦ý¹ï»´¤¤«×ªº®ð³Ýªº¨àµ£¥u¨Ï¥Î¤@¦¸§l¤J©Ê§ÜÁxÆP»s¾¯¨Ã¨S¦³Å㪺À°§U¡C ¹L¥h¯ùÆPÃþªºÃĪ«¦h¥Î¨Ó§@¬°²Ä¤@½u¥ÎÃÄ¡A¦ý¨ä«o®e©ö³y¦¨¸¡µh¡Aäú¤ß¡A¹Ã¦R¡A¤ß±ª¬Æ¦Ü¤ß«ß¤£¾ã¤Î©âµjµ¥°Æ§@¥Î¡A¦]¦¹¨Ï¥Î¤Wn®æ¥~¤p¤ß¡C¦³5½g¨Ï¥ÎÀH¾÷Âùª¼¹êÅç¤èªkªº¬ã¨s³ø§i³£¤£»{¦P»´¤¤«×ªº®ð³Ý«æ©Êµo§@ªº¯fµ£°£¤F§l¤JÂX±i¾¯¥~¦A¥[¤W¨Ï¥Îª`®g¯ùÆPÃþÃĪ«·|¦³§ó¦nªºªvÀø®ÄªG¡A¤]´N¬O¨Ã¤£·|§ïµ½ªÍ¥\¯à©ÎÁ{§É¯gª¬¡A¤]¤£·|´î¤Ö¦í°|¤Ñ¼Æ¡]Level IE¡^¡C¦Ó¹ï©ó««×ªº®ð³Ýµo§@¥[¤W¯ùÆPªº½T¥i¥H¸û¦§ïµ½ªÍ¥\¯à¤Î®ñ®ð¹¡©M¿@«×¡A¦ý©Ò¤Þ°_ªºäú¤ß¹Ã¦Rªº°Æ§@¥Î¤]ÀH¤§¼W¥[¡A¦P®É¨Ã¤£·|´î¤Ö¦í°|¤Ñ¼Æ¡C¦]¦¹¯ùÆP¨Ã«D§¹¥þ¤£¯à¥Î¡A¦ý¹ï©ó««×«æ©Ê®ð³Ýµo§@¥B¹ï¨ä¥LªvÀø¤è¦¡¤ÏÀ³¤£¨Î®É¤´¥i¨Ï¥Î¡C ¥Ñ©ó¹ï®ð³Ý¤§¯f²z¥Í²z¾Ç¦³§ó²`¤Jªº¤F¸Ñ¡A§Üµoª¢®ÄªGÅãµÛªºÃþ©T¾J«K¬Û§Î«n¡C¥Ñ¦¨¤H®ð³Ýªº¸gÅç¡A³\¦h¬ã¨sÅã¥Ü«æ©Êµo§@®É¦´Áµ¹¤©Ãþ©T¾J¥i´î¤Ö¦í°|²v¤Î´î¤Ö¦Aµo²v¡C¦Ó¨àµ£ªº¬ã¨s³ø§i¥çÅã¥Ü«æ©Êµo§@®É«Kµ¹¤©¤fªAÃþ©T¾Jªº¤@²Õ¨äªÍ¥\¯à¦³ÅãµÛ§ïµ½¤]´î¤Ö¦í°|¾÷²v¡A¦P®É©ó«æ¶E°±¯dªº®É¶¡¤]¸ûµu¡C¨Ï¥Î¦Ù¦×ª`®gÃþ©T¾J¥ç¦³¬Û¦Pªº®ÄªG¡]Level IA¡^¡C¦Ù¦×©ÎÀR¯ßª`®gÃþ©T¾J³£¦³¬Û¦Pªº®ÄªG¡C¥Ñ¥æ¤e¤ÀªRºî¦X¦UÓ¬ã¨sµ²ªGµo²{Ãþ©T¾Jµ¹¤©ªº³~®|¹ï©ó§ïµ½ªÍ¥\¯àªº®ÄªG¬O¬Û·íªº¡C¥t¤@Âùª¼¬ã¨s¤ñ¸û©ó«æ¶E®É¤À§O§ë¤©¤fªA©ÎÀR¯ßª`®gÃþ©T¾J¡A¨â²ÕªºÁ{§É§ïµ½µ{«×©Î¦í°|²v¬ÒµL®t§O¡]Level IA¡^¡C¤@¯ëªº«Øij¾¯¶q¬°prednisolone 1-2 mg./kg/day¡A¦Ü©ó¨Ï¥Î¦h¤[¤´¥¼¦³©w½×¡A¤@¯ë¬°5¦Ü7¤Ñ¡A§Y¨Ï¨Ï¥Î10¤Ñ¤]¤£»Ý³v¦¸´î¶q¡C
Á`µ² 1. ¹ï©ó¯Ê®ñªº¯f¤H®ñ®ðªº¨ÑÀ³¤´¬OºÀ³³B²zªº¨BÆJ¡]Level IIIB¡^¡C 2. §l¤J©Ê¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¬Oºò«æ³B²zªºº¿ï¥ÎÃÄ¡]Level IA¡^¡C 3. ¹ï©ó««×¯f¤H§l¤J©Ê§ÜÁxÆP»s¾¯¥i¥[¤J§l¤J©Ê¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¦X¨Ö¨Ï¥Î¡]Level IB¡^¡C 4. «æ©Êµo§@®É¥Î¯ùÆP¨Ã¤£·|§ïµ½¯gª¬¡A¦ý¥i¯à³y¦¨°Æ§@¥Î¡]Level ID¡^¡C 5. ¦´Á¨Ï¥ÎÃþ©T¾J¬O¥²nªº¡]Level IA¡^¡C
ºC©Ê³B²z ¥Ø«eªvÀø®ð³Ýªº¥D¬y¤´¬O¥Î§l¤J©ÊÃþ©T¾J¡]Level IA¡^¡ACalpinµ¥¤H¤ÀªR¹L¥h20¦~¨Ó¨Ï¥ÎÂùª¼ÀH¾÷¹ï·Ó±±¨îªº¹êÅç¤èªk±´°Q§l¤J©ÊÃþ©T¾J¨ÓªvÀø¨àµ£®ð³Ýªº24½g¤å³¹¡A¾ãÓ¥æ¤e¤ÀªRµ²ªGµo²{¥§¡¨Ï¥Î§l¤J©ÊÃþ©T¾J8©P¥i§ïµ½Á{§É¯gª¬¡A´î¤Ö¨Ï¥Îºò«æµo§@®É¨Ï¥Î¤ä®ðºÞÂX±i¾¯ªº¾÷·|¡A´î¤Ö¨Ï¥Î¤fªAÃþ©T¾Jªº¾÷·|¡A¥H¤Î§ïµ½ªÍ¥\¯àµ¥¡C¨Ï¥Î§l¤J©ÊÃþ©T¾Jªø¹F¤@¦~ªº®ð³Ý¨àµ£ªº§ïµ½µ{«×¤]¸û¨Ï¥ÎSodium cromoglycateªº¤@²Õ®ÄªG¦n( Level IA)¡C¦b½T©w¶EÂ_¬°®ð³Ýªº¨àµ£¦´Á¨Ï¥Î§l¤J©ÊÃþ©T¾J·|¤ñ¨S¦³¨Ï¥Îªº¤@²Õ¦³¸û¨ÎªºªvÀø®ÄªG¡C§Y¨Ï¦¥ý¨S¦³¨Ï¥Î¤J©ÊÃþ©T¾J¦Ó«á¦A§ï¥Î¤§¡A¨ä³Ì«áªÍ¥\¯àªºªí²{¤]¤ñ¦´Á«K¶}©l¨Ï¥Î§l¤J©ÊÃþ©T¾Jªº¤@²Õ®t(Level II)¡C
u ¦³Ãö¨Ï¥Î§l¤J©ÊÃþ©T¾JªvÀø®ð³ÝªºÃÒ¾Ú
From Evidence-based Asthma Management B.C. Decker 2001
¹ï©ó§l¤J©ÊÃþ©T¾J³Ì¬°¤j²³©ÒÃö¤ßªº²ö¹L©ó¬O§_¦³°Æ§@¥Î¡H¬O§_·|¼vÅT¨àµ£¦¨ªø¡H°w¹ï21¶µ¬ã¨sÁ`¦@810¦ì¨àµ£©Ò°µªº¥æ¤e¤ÀªRµo²{ªø´Á¨Ï¥Î§l¤J©ÊÃþ©T¾J¡]Beclomethasone dipropionate¡^ªvÀø®ð³Ý¯f¤£·|¼vÅT³Ì«á¨°ª¡A¦P®É«Øij¨Ï¥Î¾A·í¾¯¶q(¤p©ó600 micrograms/day)ªºBeclomethasone dipropionate¨Ã¤£·|¼vÅT¥Íªø¡C¨ä¥Lªº¬ã¨s«hÃÒ©ú¨Ï¥Î¸û°ª¾¯¶qªº§l¤J©ÊBeclomethasone dipropionate·|¤ñ¨S¦³¨Ï¥Îªº¤@²Õ·|¼vÅT¦¨ªø³t«×¡]Level IA¡^¡C¤£¹LÁö¬O§l¤J©ÊÃþ©T¾J¦ý¤´¦³¤£¦PºØÃþ·s¬ãµoªº§l¤J©ÊÃþ©T¾J¡C¦Ü¤Ö¦³3¶µ¬ã¨sµo²{ªø´Á¨Ï¥Î§l¤J©ÊFluticasone propionate¨Ã¤£·|§í¨î¦¨ªø³t«×¡]Level IB¡^¡C¦b²³¦hªº¬ã¨s¤¤§l¤J©ÊÃþ©T¾J»P¥ÍªøªºÃö«Y³£¨Ï¥Îknemometry´ú¶q»Lªø¡A¦Ó¹ê»Ú¤W¨àµ£¦¨ªø¨Ã¤£¤@©w¬O§eéw¥B¥§¡ªº¦¨ªø¡A¦Ó¦³¥i¯à¤@¬q®É¶¡°±º¢¦Ó¥t¤@¬q®É¶¡§Ö³t¦¨ªø¡A¦Óknemometry¬O§_´N¯à¥Nªí¨àµ£¦¨ªøª¬ªp¤´»Ý¦Ò¼{¡C®ð³Ý¥i¯à·|P©R¡A®ð³Ý±±¨î¤£¦n¤]·|¼vÅTµo¨|¡A¦b²³¦hÃÒ¾Ú¤ä«ù¨Ï¥Î¾A·í¾¯¶qªº§l¤J©ÊÃþ©T¾J¯à¦³®Ä±±¨î®ð³Ý¡C¤ñ¸û¨ä¥i¯à¼vÅT¥Íªøµo¨|¤Î®ð³Ý¯gª¬±±¨îªº«n©Ê¡A¤Î¦¨Ï¥Î§l¤J©ÊÃþ©T¾JÀ³¬O¸û¦nªº¿ï¾Ü¡A¦Ó±±¨î®ð³Ýéw¤]¹ï¨àµ£¦¨ªø¦³©Ò§U¯q¡C §l¤J©ÊCromolyn Sodium¬O¤@·¥¦w¥þªºÃĪ«¡C³\¦h¤j«¬ªºÀH¾÷Âùª¼¸ÕÅçÃÒ©ú¨ä¥i¸û¹ï·Ó²Õ¦³®Äªº±±¨îºC©Ê®ð³ÝªºÃ©w¡A¦³®Äµ{«×¦Ü¤Ö©M¯ùÆPÃþ¬Û·í¡]Level IA¡^¡C¦ý¤]¦³³\¦hÃÒ¾ÚÃÒ¹ê¨äÁ{§É®ÄªG¸û§l¤J©ÊÃþ©T¾J®t¡C¦]¦¹¹ï©ó¾ÇÄ֨ൣ«ØijY±`¥Î¨ìµu®Ä«¬ÂX±i¾¯¨Ó±±¨î¤ÏÂеo§@ªº®ð³Ý¯gª¬®É¥i¥[¤Wªø´Á§l¤JCromolyn sodium¡A ¹j¤»¶gY®ÄªG¤´¤£¨Î¥i¦A¥[¤W§C¾¯¶q§l¤J©ÊÃþ©T¾J¡C¹ï©ó¾ÇÄÖ«eªº¨àµ£¨Ã¨S¦³«Ü¦nªº¬ã¨s¤ÎÃÒ¾Ú¤ä«ù¨ä®ÄªG¡A¦ý¤´¥i¾A¥Î¦p«e©Òz¾ÇÄÖ´Á¨àµ£½Õ¾ã¥ÎÃĪº¨BÆJ¡C ¡@¡@ªø®Ä«¬¤ä®ðºÞÂX±i¾¯ªºÃĮĥiºû«ù12¤p®É¥ª¥k¡C¬ã¨sµo²{¨C¤Ñ§l¤Jªø®Ä«¬¤ä®ðºÞÂX±i¾¯·|¤ñ¹ï·Ó²Õ§ó¦³¹w¨¾®ðºÞÁYªº±¡§Îµo¥Í¡C¬Æ¦Ü³sÄò¨Ï¥Î12Ó¤ë¤]¯àºû«ù«Ü¦nªºªÍ¥\¯à¡A¨ÃµL¤@¯ëµu®Ä«¬¤ä®ðºÞÂX±i¾¯¦b¨Ï¥Î¤@¬q®É¶¡«á·|²£¥Í@¨ü©Êªº±¡§Î¡C§Q¥ÎÀH¾÷Âùª¼¸ÕÅç°w¹ï»´«×®ð³Ýªº¨àµ£±N§l¤J©ÊÃþ©T¾J¡Aªø®Ä«¬¤ä®ðºÞÂX±i¾¯¤Î¦w¼¢¾¯¤À¦¨3²Õ¨Ï¥Î1¦~«áµo²{§l¤J©ÊÃþ©T¾J(Beclomethasone)¹ï®ð³Ý±Ó·P«×ªº§ïµ½³Ì¦n¡A¦ýµu´Á¤º¹ï¨°ªªº¼vÅT¤]¬O3²Õ¤¤³Ì©úÅ㪺¡C¥t¤@¶µÃþ¦üªº¬ã¨s¤D°w¹ï¤¤««×®ð³Ýªº¨àµ£§@¤ñ¸û¡A¦bªÍ¥\¯àªº§ïµ½¤´¬O§l¤J©ÊÃþ©T¾J¤@²Õ¦³³Ì¦nªº®ÄªG¡A¦P®É¤£«Øij³æ¿W¨Ï¥Î§l¤J©Êªø®Ä«¬¤ä®ðºÞÂX±i¾¯§@¬°®ð³Ýªºªø´Á±±¨îÃĪ«(Level IE)¡C¹ï©ó®ð³Ý¯gª¬±±¨î¤£¦n®É¡A¦X¨Öªø®Ä«¬¤ä®ðºÞÂX±i¾¯»P§l¤J©ÊÃþ©T¾J»P¼W¥[§l¤J©ÊÃþ©T¾J¾¯¶q¤ñ¸û¡A¤GªÌ¦³¬Û¦üªº®ÄªG(Level IA)¡C¥Ø«e¤´«Øij»P§l¤J©ÊÃþ©T¾J¦X¨Ö¨Ï¥Î(Level IA)¨ÓªvÀø®ð³Ý¡C¹ï©ó¦]¹B°Ê¦Ó»¤µoªº®ð³Ý¡A¹w¥ý¨Ï¥Îªø®Ä«¬¤ä®ðºÞÂX±i¾¯¦³¹w¨¾µo§@ªº¦n³B¡C¦ý¨ä¨Ã¤£¾A¥Î©ó«æ©Êµo§@®Éªººò«æ³B²z¥ÎÃÄ¡C ¥Õ¤T²m¯À½Õ¸`¾¯¬OªvÀø®ð³Ýªº·sÃÄ¡C¹ï©ó¤¤««×®ð³Ýªº¯f¤H¥i§ïµ½ªÍ¥\¯à¡A´î¤Ö©]«y¡A´î¤Ö¨Ï¥Î¤fªAÃþ©T¾J©Îµu®Ä«¬¤ä®ðºÞÂX±i¾¯ªº¾÷·|¡C¹ï©ó¤w¨Ï¥Î§l¤J©ÊÃþ©T¾J¦ý®ð³Ý¼xª¬¤´±±¨î¤£¨Îªº¯f¤H¥[¤W¥Õ¤T²m¯À½Õ¸`¾¯ªº½T¦³¸û¦nªº§ïµ½(Level IA)¡C¥t¥~¹ï©ó¹B°Ê»¤µoªº®ð³Ý¥ç¦³ªvÀø®ÄªG(Level IA)¡CÁöµM¦X¨Ö§l¤J©ÊÃþ©T¾J¨Ï¥Î¦³¥[±jªº®ÄªG¡A¦ý¥Ñ©ó¨ÃµLªø´Á¨Ï¥Îªº¬ã¨sÃÒ¾Ú¡A¦]¦¹»Ýn§ó¦hªº¤ñ¸û¬ã¨s¨ÓÃÒ©ú¨ä®ÄªG¡C
Á`µ² 1. §l¤J©ÊÃþ©T¾J¬O³Ì¦³®Ä±±¨î®ð³ÝªºÃĪ«¡A¦ý¨Ï¥Î¤´¦]¤H½Õ¾ã¡]Level IA¡^¡C 2. Inhaled Cromolyn («|¹F¥Ã¼Ö)¬O¦w¥þ©Ê³Ì°ªªºÃÄ¡A¦ý®ÄªG¸ûÃþ©T¾J®t¡]Level IC¡^¡C 3. ªø®Ä«¬¤A¤G«¬¥æ·P¯«¸g¿³¾Ä¾¯¥i´î¤ÖÃþ©T¾J¾¯¶q(Level IB)¡C 4. ¥Õ¤T²m¯À½Õ¸`¾¯¥Î©ó»´«×®ð³Ý¡A´î¤Ö¹B°Ê»¤µo®ð³Ý¡A´î¤ÖÃþ©T¾J¨Ï¥Î¶q¡]Level IA¡^¡C 5. ®ð³Ý½Ã±Ð«n©Ê¤é¼W¡]Level IB¡^¡C 6. ¯ùÆP»ù®æ«K©y¡A¦ýÀ³¥Î¤W¦³¡]Level IC¡^¡C 7. ÁקK¹L±Óì¤Î¨ë¿Eª«±`³Q©¿²¤¦ý¤´«n¡]Level IB¡^
µ²½× ¥Ñ©ó¨àµ£®ð³Ý¯f¤é¯q¼W¦h¡AµLºÃ®ø¯Ó¤F³\¦hªÀ·|¦¨¥»¡C½Ã¥Í¸p¥ç°Ñ¦ÒGINA (Global Initiative for Asthma)²Õ´q©w¤§¡i®ð³Ý«ü¤Þ¡j¤Î¬ü°ê°ê®a½Ã¥Í¬ã¨s°|»P¥@¬É½Ã¥Í²Õ´¦X½s¤§¡i®ð³Ý¶EÀø«ü¤Þ¡j¡Aq©w¦X¥G°ê¤Hªº¡i®ð³Ý¶EÀø«ü¤Þ¡j¡C¦Ó³o¨Ç«ü¤Þ¤¤¹ï©ó®ð³Ýªº³B¸m¤]³£¬O¨Ì¹êÃÒÂå¾Çªººë¯«¡A¨CÓ¨BÆJªº¥ÎÃÄ¥²¶·¦³³\¦h¬ã¨sÃÒ¾Úªº¤ä«ù¡A¯à¦b¹ï¤HÅé¦w¥þªº«e´£¤U³Ì¦³®Äªº±±¨î®ð³Ý¡C¦Ü©ó«ü¤Þªº¸Ô²Ó¤º®e¦]½g´T¦³¡A¦b¦¹¤£¦h´yz¡A¤]¥iµ¹ÂåÅ@¤Hû¤Î¤j²³¹ï®ð³Ý¦³§ó²M·¡ªº·§©À¡C¦Ü©ó¤]¦³³\¦h¥tÃþªº®ð³ÝªvÀø¤è¦¡¡A¦³®Ä»P§_¦bÁ¿¨DÃÒ¾ÚÀu¥ýªºÂå¾Ç»â°ì´N¥²¶·¾a¤ÏÂФÎÄYÂÔªº¹êÅç¤Î®É¶¡¨ÓÅçÃÒ¡C
°Ñ¦Ò®Ñ¥Ø 1. Evidence-based Asthma Management. J Mark FitzGerald, P. Ernst, LP Boulet, PM O¡¦Byrne. B.C. Decker. 2001 2. Evidence-based Pediatrics. William Feldman. B.C. Decker. 2000 3. Evidence-based Pediatrics and Child Health. VA Moyer, EJ Elliot, RL Davis et al. BMJ Book. 2000 4. ®ð³Ý¶EÀø«ü¤Þ¡C¦æ¬F°|½Ã¥Í¸p 89¦~1¤ë¥Xª© ¡@ ¡@ ¡@ |
||||||
ªø©°¨àµ£Âå°|¨àµ£¹L±Ó®ð³Ý·Àã¬ì¥DªvÂå®v ¸°ê°¶ Âå®v
³Ìªñ¤@³s¦êªº¦Y¿ùÃÄ¡A¥´¿ù°wªº·s»DÁ`¬OÅý¤H¼~¤ßÊÝÊÝ¡A°£¤F§Æ±æÂå®v¯àÃĨì¯f°£¥~¡A²`©ÈÂå®v¶}¿ùÃÄ¡A©Î²£¥Í°Æ§@¥Î¡CÃĪ«¦³¤d¸UºØ¡A·sÃĪº¬ãµo¤W¥«§ó¬O¤é¦³©Ò»D¡AÁa¨Ï¬OÂåÃĬɮõ¤æ¤]¤£¯à¤F¸Ñ©Ò¦³ÃĪ«ªº§@¥Î©Î¥Îªk¡C¨ä¹êÃIJzª¾ÃÑÁöÁ}²`ÃøÀ´¡A¦ý¬O¨Ï¥ÎÃĪ«½T»P¤é±`¥Í¬¡®§®§¬ÛÃö¡A¦óªpÃĪ«¬O§@¥Î¦b¦Û¤v¨¤W¡A¥unµy¥[ª`·N«K¥i¦h¤@¤À¦w¥þªº«O»Ù¡C´Nºâ¬Oºû¥L©RÃĤY¤]ºâ¬O¤@ºØÃĪ«¡A¦Y¦h¤F¤£·|§ó°·±d¡A¤Ï¦Ó·|¦³°Æ§@¥Î¡C
1. »â¨ìÃĮɥý¬Ý²M·¡¬O§_®³¨ì¬O¦Û¤vªºÃÄ¡A¦³®É¦£¤¤¦³¿ù®³¨ì§O¤HªºÃÄ¡A©Ò¥H¥ý¹ï¹ï¬ÝÃijU¤W¬O§_¬O¦Û¤vªº¦W¦r¡C 2. ¬Ý²M·¡ÃĪ«ªººØÃþ¡A²{¦b¦h®aÂå°|ÃijU¤W·|µù©úÃĪº¦¨¤À¤Î§@¥Î¡A¥ý½T©w¬O§_¬O¦X¥G¦Û¤vªº¯gª¬¡C¨Ò¦p©ú©ú¬O·P«_«y¹Â¡AÃijU¤¤«ç»ò¦³°¦åÀ£ÃÄ¡H¦³¥ô¦ó¥ÎÃĺü{À³¦b¸ß°ÝÂå®v¸Ô±¡¡C 3. ¦YÃÄ«e¬Ý²M·¡ÃijU¤Wªº»¡©ú¤Î¥Î¶q¥Îªkµ¥¡A¦³ªº¬O¶º«eªA¥Î¡A¦³ªº¶º«á¤~¦Y¡A³o¨Ç³W©wµL«D¬O§Æ±æÃĪ«¯àµo´§°µ¤jªº®ÄªG¡A¥H§K¼vÅTÃĪ«ªº§l¦¬¡C¨Ã¤£¬O¶º«á¦Y¤~¤£·|¶ËG¡C¤£¹LY»{¯u·ÓÂåÅñ¦YÃÄ¡A¤@¤Ñ¥i¯àn¦Y¤Q¼Æ¦^ªºÃÄ¡A·|¦Y¨ìÀY¥Öµo³Â¡C¥i½Ð±ÐÂå®v¥i§_¥H¤@°_ªA¥Î¡C 4. ¦³¨ÇÃĪ«¨Ã¤£¾A¦X¥[¤J¤û¥¤©ÎªG¥Ä¤¤¡A¤@¨Ó¥i¯à´î§CÀø®Ä¡A¦AªÌ¥i¯à§ó·|¤Þ°_°Æ§@¥Î¡C¤£¹L¤]¤£n³x^¶¯³á¡A¬°¤Fªí¥Ü«i´±¦Óª½±µ§]ÃÄ¡AYÃĪ«¦b¹¹D·»¤Æ¡A¤Ï¦Ó¥i¯à³y¦¨¹¹Dµoª¢¡C©Ò¥H³Ì¦nÁÙ¬O²VµÛ¶}¤ô§]ªA¡C 5. ¦³®É¤@¤Ñn¦Y¦n¦h¦¸ÃĩΤ@¦¸n¦Y¦n¦hºØÃÄÁöµMı±o«D±`³Â·Ð¡A¦ý¤´«Øij¨Ì·Ó«ü¥ÜªA¥Î¡AÅýÃĪ«¹F¨ì³Ì¦nªºÃĮġAYÂ_Â_ÄòÄò¦Y¤£¶ÈµLªkµo´§¨äÃĮġA¦³¨ÇÃĦp§Ü¥Í¯À§ó·|¦]¦¹³y¦¨§ÜÃÄ©Ê¡C 6. ÃĪ«¤]©M¹«~¤@¯ë¤]¦³«O¦s´Á¡A³£·|¼Ð¥Ü¦bÃIJ~©ÎªÅ²°¤W¡A¹L´Á¤F¤]¤£nªA¥Î¡C 7. ¦Û¤v¦Y¤F¦³®ÄªºÃĤ]¤£n®³µ¹§O¤H¥Î¡A¦]¬°¨CÓ¤Hªº¯f±¡¤ÎÅé½è¤£¨£±o¬Û¦P¡AÁÙ¬On¸gÂå®vªºµû¦ô¤Î³B¤è¤~¦n¡C
¥ÎÃĦw¥þ¤£¥u¬OÂå®vÃÄ®vªº³d¥ô¡A¦Û¤v§óª`·N¤]¦h¤@¤À«O»Ù¡C ¡@ ¡@ ¡@ |
||||||
ªø©°¨àµ£Âå°|¨àµ£¹L±Ó®ð³Ý·Àã¬ì¥DªvÂå®v ¸°ê°¶Âå®v
À¦¥®¨à³Ì±`¨£ªº©I§l¹D¯e¯f°£¤F¤@¯ëªº³ïÄVµoª¢¡B«y¹Â¡B¬y»ó¤ôµ¥¤W©I§l¹D·P¬V¥~«K¬O¤U©I§l¹D·P¬V¡A¨ä¤¤³Ì±`µo¥Íªº¬O©Ò¿×«æ©Ê²Ó¤ä®ðºÞª¢¡A³o¤]À¦¥®¨à¦í°|¬O³Ì±`¨£ªºì¦]¡C¥V©u¯f¬rÄøÄø±ý°Ê¡A²{¦b¥i¬O¦nµoªº©u¸`¡A®aªø¥in¦hª`·N¡C
«æ©Ê¤ä®ðºÞª¢¥Dn¬O¦]¯f¬rªº·P¬V³y¦¨¡A³Ì±`¤Þ°_ªºP¯f¯f¬r¬°©I§l¹D¿Ä¦X¯f¬r¡A¨ä¥L¦p°Æ¬y·P¯f¬r¡B¸¢¯f¬rµ¥¤]³£¥i¯à³y¦¨Ãþ¦üªº¯gª¬¡C¥Dn¬OÂǥѸªj¶Ç¬V¡A¦]¦¹®a¤¤Y¦³¸û¤jªº¤pªB¤Í·P«_«K®e©ö¶Çµ¹¨ä¥Lªº¤pªB¤Í¡C³\¦h®aªø¯Ç´e¤pÀ¦¨à«OÅ@ªº«D±`¦n¡A¤]¨S¦³±a¥Xªù¡A¦Ó¥B®a¤¤¤]¥u¦³³o¤@ÓÄ_¨©¡A«ç»òÁÙ·|³Q¶Ç¬V¡H¨ä¹ê®aªø¦b¥~¤u§@¡A¥X¤J¤½¦@³õ©Ò«K¦³¥i¯à³Q¶Ç¬V¡A¥u¬O³o¨Ç¯f¬r¨I¿n¦b§Ú̪º»óµÄ©Î³ïÀY¡A¦ý¤j¤H¥i¯à¦¦³©è§Ü¤O©Ò¥H¨S¦³ªí²{¥X¥ô¦ó¯gª¬¡A©Î¥u¬Oı±o³ïÄV©Ç©Çªº¦Ó¤w¡A¦ý´N¦³¥i¯à¦]¦¹¦Ó¶Ç¬Vµ¹¤pªB¤Í¡C·P¬Vªì´Á®É¤]³\¥u¬O¥´¼QÀ¡¡B¬y»ó¤ô¡Bµo¿Nµ¥»´·L¯gª¬¡Aº¥º¥¦a«K¥X²{©I§l«æ«P¡A©I§l®ÉÅ¥±o¨ì³Ý»ïÁn¡B·ðÁnµ¥¡A§ó¬ÆªÌ¥iÆ[¹î¨ì¤pªB¤Í»óÁlݵ°Ê©Î¦Ø°©¤U½t·|©úÅã¥W³´¡A³o³q±`ªí¥Ü¤pªB¤Í©I§l§xÃø¡A»Ýn¥Î¨ì»²§U©Êªº©I§l¦Ù¦×¡C¦³®É®aªø¤â´x¶K¦b¨àµ£ªºI³¡³£¥i·P¨ü¨ì·ð¦bªÍ³¡¤º®¶°Ê¡C¤pªB¤Í³o¼Ëªº¤£µÎªA¦ÛµM¹¼¤°§C¡Bļ°Ê¤£¦w¡BºÎ¯v¤£Ã¤F¡C
³y¦¨³o¼ËªºÁ{§Éªí²{¥Dn¬O¤pªB¤Íªº¤p¤ä®ðºÞ¦]¯f¬r·P¬V¦Ó³y¦¨¤p¤ä®ðºÞµoª¢¸~µÈ¨Ã»W¿n·ð²G¡A¦]¦¹¦b쥻´N«Ü¤pªº²Ó¤ä®ðºÞ¤Sµo¥Í¤Fªý¶ë¡A¦ÛµM³y¦¨©I§l«æ«P§xÃø¤F¡A¦Ó¦b¸û¤jªº¤pªB¤Í©Î¦¨¦~¤H¡A§Y¨Ï¦³·ð²G¡A¦ý¦]®ðºÞªººÞ®|º¥º¥¦¨¼ô¡B¼W¤j¡A¬Û¹ïªºªý¶ëªºµ{«×´N¤£·|¼vÅT¤Ó¤j¤F¡A©Ò¥H²Ó¤ä®ðºÞª¢³oÓÂå¾Ç¦WºÙ¥i»¡¬O¨â·³¥H¤U¨àµ£ªº±M§Q¡C
¤p«Ä±o¨ì²Ó¤ä®ðºÞª¢¡A¤£¶È¤pªB¤ÍÃø¨ü¡A¤÷¥À¥²©w¤]¾á¤ß¤S¤ß¯k¡A¥u¥i±¤¨ì¥Ø«e¬°¤î¨Ã¨S¦³¯S®Ä¨}¤è°w¹ï¦¹¯fªvÀø¡C¦]¬°¬O¯f¬r·P¬V¡A©Ò¥H§Ü¥Í¯À¬O^¶¯µL¥ÎªZ¤§¦a¡A§Y¨Ï¦³·ð¡A¨ä¹êªA¥Î«y¹Â¤Æ·ðªºÃĮĪG¦³¡A³o®É¥Î¬y»ó¤ôªºÃĨӪvÀø¬y»ó¤ô¡A¦³®É¤Ï¦Ó·|Åý·ðÅÜÂH¸Y¦Ó¤£©ö±Æ¥X¡C¦Ón¤Æ·ð¥H§K·ð¿n¦b²Ó¤ä®ðºÞ¤¤¡A³Ì«nªº¡uÃÄ¡v¨ä¹ê¬O¡u¤ô¡v¡C¤pªB¤Í©I§l«æ«P¨ä¹êµL§Î¤¤¦b©I®ð®É«K©I¥X¤F³\¦h¤ô¥÷¡A¦A¥[¤W¦]¨Å餣µÎªAG¤f¤£¦n¡A¶i¹ªº¶q¤]´î¤Ö¡A¤ô¥÷ªºÄá¨ú¦ÛµM¸òµÛ´î¤Ö¡A©Ò¥H¦bÃÒ¾ÚÂå¾Ç¤¤¡AªvÀø²Ó¤äºÞª¢³Ì«nªº¤èªk¬O¡u¸É¥R¤ô¡v¡C¦Ü©ó§l¤J¤ä®ðºÞÂX±i¾¯¨Ó§ïµ½³Ý»ïªº²{¶H¡A¨Æ¹ê¤WÀ°§Uªº®ÄªG¦³¡CY¦í°|¤@¯ë·|µ¹¤©Àã¼íªº®ñ®ð¥Î¥HÀ°§U¼íÀã²Ó¤ä®ðºÞ¤ºªº·ð¡F¦b®a¸Ì¥i§Q¥Î¯D«Ç¤º©ñ¼ö¤ô§Î¦¨ªº¤ô»]®ð¨ÓÀ°§U¤Æ·ð¡A¥t¥~¥i¥H±N¤pªB¤Íw©ñ¦b¤j»L¤W¡A¨{¤l¹ÔÓ¤p¤ò¤y§Î¦¨ÀY§C¸}°ªªº«º¶Õ¡A±N§Ú̪º¤â´xÅs¥W§Î¦¨ªMª¬¡A¦©À»¤pªB¤ÍªºI³¡¡A¾A·í¥X¤O©ç·ð¨ÓÀ°§U¤pªB¤Í«y·ð¡C¤£¹L¤@¤è±¤pªB¤Í¤£¨£±o°t¦X¡A®e©ö§á°Ê¡F¥t¤@¤è±®aªø¤ß¯k¤£´±¥Î¤O©çÀ»´N¨S¦³®ÄªG¡A¨ä¹ê©ç·ð¥¿½T¤pªB¤Í¨Ã¤£·|¨ü¶Ë©Îµhªº¡C
¦Ü©óªÍª¢¬O«üªÍ¹ê½è¦]·P¬V²£¥Íªºµoª¢¤ÏÀ³¡A¤]´N¬O¤U©I§l¹Dªº²Ó¤p¤ä®ðºÞ¡AªÍªw¡AªÍªwÅnµ¥³£µoª¢¤F¡C¦P¼Ëªº¤]¬OÂǥѪŮ𤤪º¸ªj¶Ç¬Vªº¡A¤£¹L¦b¤£¦Pªº¦~ÄÖ¼h¦³¥i¯à¦³¤£¦Pªº·P¬V·½¡CÁ{§É¤Wn¥Ñ·ð²G©Î¦å²G°ö¾i¥Xªv¯f²Óµßªº¾÷²v¨Ã¤£°ª¡A©Ò¥H¥u»Ý¥Ñ¯Ý³¡X¥ú¤ÎÁ{§É¯gª¬«K¥i¶EÂ_¡C¨Ò¦p¦b¤@Ó¤ë¤j¥H¤Uªº·s¥Í¨àªÍª¢¦h¬OB±ÚÃì²yµß¬°¥D¡F¸û¤jªºÀ¦¨à©Î¨àµ£ÁÙ¬O¥H¯f¬r¤Þ°_ªºªÍª¢¬°¦h¡A¦Ü©ó²Óµß¤Þ°_ªºn¦Ò¼{B«¬¶Ý¦å±ìµß©ÎªÍª¢Âù²yµß¡F¾ÇÄ֨ൣ°£¤FªÍª¢Âù²yµß¥~±`¨£¤@ºØºÙÅð¼ßµßªÍª¢¡A¨ä«D²Óµß¤]«D¯f¬r¡A¤@¯ë¯gª¬¨Ã¤£ÄY«¡A©¹©¹¥i¤£ÃĦÓ¡¡C¦]¦¹Âå®v®Ú¾ÚÁ{§É¯gª¬©Î¥²n®É©Ò·Óªº¯Ý³¡X¥ú¨Ó¤U¶EÂ_¡AY»{©w¬O¯f¬r©Ê·P¬V¨Ã¤£»Ý§Ü¥Í¯ÀªvÀø¡A¤]¤£¤@©w¦³¶À·ð´N¤@©wnªA¥Î§Ü¥Í¯À¡CY§P©w¬O²Óµß©ÊªÍª¢«h·|®Ú¾Ú¤£¦Pªº¦~ÄÖ¼h¥i¯à·P¬VªºµßºØµ¹¤©¾A·íªº§Ü¥Í¯À¡C
§Ü¥Í¯Àªºµ¹¤©¬O¨Ì·Ó¯fªp¤ÎµßºØ¦Ó¿ï¾Ü¡A©Ò¥H§Y¨Ï¶EÂ_¬°ªÍª¢Y¬O¹³¯f¬r·P¬V¨Ã¤£»Ý§Ü¥Í¯ÀªvÀø¡A¤ôªº¸É¥R¤´¬O³Ì«n¡CY¬O²Óµß©ÊªÍª¢¤]¤£¥²ÄߩȧܥͯÀªº°Æ§@¥Î¡A¤@©wªºÀøµ{¨Ã¤£·|¶Ë¨x¶ËµÇªº¡A¾A·íªºªvÀø¤~¯àÃĨì¯f°£¡C¥t¥~«ezªº©ç·ð¤Î¸É¥R¤ô¥÷¤´¬OªvÀøªº¤£¤Gªkªù¡C¦ýY¬OÂå®v§PÂ_¿ù»~¡A»~±N²Óµß©Ê·P¬V·í¦¨¯f¬r·P¬V¦Ó¨S¥Î§Ü¥Í¯À·|¤£·|©µ»~¯f±¡¡H©ÎªÌ°®¯Ü¥ý¦Y§Ü¥Í¯À¥H¨¾¸U¤@¡H¦p¦¹«K®e©ö³y¦¨§Ü¥Í¯ÀÀݥΡA©ö³y¦¨§ÜÃÄ©Ê¡C¦]¦¹Á{§É¶EÂ_»PªvÀø¬O¸gÅ窺²Ö¿n¡Aª¾ÃѪºÀ³¥Î¡A¤]¬O¤@ªùÃÀ³N¡A·íµM¤]¦³¨ä·ÀI©Ê¡A¦ý¤]µ´¤£¯à¶Ãºj¥´³¾¡A±N©Ò¦³¥i¯àªº¥ÎÃĤ@°_µ¹¤©¡A¨º»ò¨CÓ¤H«K³£¦¨ÃÄÅø¤l¤F¡C¤£¹L¤@¯ë²Óµß©ÊªÍª¢ªºÁ{§Éªí²{¸ûÄY«¡A¯fµ{¶i¦æªº¸û§Ö¡A¤pªB¤Íªº¬¡°Ê¤OÅÜ®t¡C©Ò¥H¤p¨à¬ìÂå¥Íµû¦ô¤pªB¤Íªº¯f±¡¨Ã¤£¬O«ü¾aµo¿Nµ{«×¡A¤]´N¬O§Y¨Ïµo¿N¨ì40¢J¡A¤]¤£¤@©w¥Nªí¬OÄY«·P¬V¡A¤pªB¤Íªº¹¼¤¡Aºë¯«¡A¤Î¬¡°Ê¤O³£¬O«nªº°Ñ¦Ò«ü¼Ð¡CÁ|¨Ò¦Ó¨¥¡A¤pªB¤Íµo¿N«y¹Â¦³·ð¡A·Ó¤FX¥úµo²{©úÅã¥kªÍ¦³ªÍª¢¡A¦ý¬OÁÙ¬O¬¡Â۶øõ¡A¤£¤Ó¹³ÄY«¥Í¯f¡A³o®ÉÁ{§É¤W·|¦Ò¼{¬OÅð¼ßµßªÍª¢¡A¤]³\¦Y¦Y¬õÅð¯ÀÃþªºÃÄ«K¥i§ïµ½¤F¡C
²Ó¤ä®ðºÞª¢©Î¯f¬r©ÊªÍª¢¬O¦ÛµM·|¦nªº¯f¡A§Ú̪ºªvÀø¬OÀ°§U¤pªB¤Íªº¦]¯gª¬±a¨Óªº¤£µÎªA¡AµM¦Ó³Ì²«K¥B³Ì¦³®ÄªºªvÀøÃĪ«¤£¬O«y¹ÂÃÄ¡B©Ä·ðÃÄ¡A¦Ó¬O¥²HµL©_¥BÀH¤â¥i±oªº¡u¤ô¡v¤Î®aªøªº@¤ß¤F¡CY¤£©¯·P¬V¨ì²Óµß©ÊªÍª¢´N¥²¶·¥[¤W§Ü¥Í¯À¬Æ¦Ü¦í°|¡C§¡¿ÅÀç¾i¡A®É±`¬~¤â¥i¥H´î¤Ö·P¬Vªº¾÷·|¡A¨ä¹ê¤pªB¤Í¨Ã¤£¯Ü®z¡A¨C¤@¦¸ªº·P¬V¤]³£¦bÁëÁå§Ú̪º§K¬Ì¤O¡C ¡@ ¡@ ¡@ |
||||||
¤pÄ_Ä_ºÎı·|¥´©I¡A¬O¤£¬O»ó¶ë·P«_¤F¡H¨¬°¤÷¥ÀÃø§Kºò±i¦ÛµM·|´M¨DÂåÀø¨ó§U¡C¤p¨à¬ìÂå®v¦b¬Ý¤p¯f¤H®Éº¥ý«K¬Oª`·N¦~ÄÖ¡A¦]¬°¤£¦P¦~ÄÖ¼h¦³¨ä¤£¦Pªº¦nµo¯e¯f¡A§Y¨Ï¦P¼Ë¬O¥´©Iªº¯gª¬¤]·|¦³¤£¦Pªº¦Ò¶q¡C ³\¦h·s¥Í¨à©ÎÀ¦¨à¦b³Ü¥¤©ÎºÎı®É±`·|¸û¤jªº»ó®§Án¡A¦n¹³¤p½Þªº¥sÁn¡AºÎı®É¬Æ¦Ü·|¥´©I¡Cªì¬°¤÷¥Àªº®aªø«K¾á¤ß¤pÄ_¨©·P«_¤F¡A²¦³º¥L̬ݰ_¨Ó¨º»òªº¼b®z¡A¨ì³B¨DÂå¦ý½TµLªk§ïµ½¯gª¬¡C¨ä¹êè¥X¥Íªº·s¥Í¨à¨ä¦ì©ó³ïÄV³¡¦ìªº¸¢¼ËÅé¡A©|¥¼§¹¥þ°h¤Æ¡A¦]¦¹¦b§l¥¤®É¡A©Î©]Áñ¤HÀR®É¡A¥i¯à·|Å¥¨ì¥´©IªºÁnµ¡AµM¦Ó³o½T¬O¥¿±`ªº²{¶H¡A¦pªG·í¦¨·P«_ªvÀø¦ÛµM¬OÃĥ۪ɮġC©Ò¥H¤@¤è±¥iÆ[¹î¤pªB¤Íªº©I§l³t²v¡A·s¥Í¨à¤£¤ñ¦¨¤H¡A¤@¯ë¤@¤ÀÄÁ©I§l26-28¤U¬O¥i±µ¨üªº¥¿±`½d³ò¡C¥t¥~¥iÆ[¹î¬O§_¦³»óÁlݵ°Ê©Î¦Ø°©¤U¥W³´µ¥©I§l«æ«Pªºªí²{¡C¨ä¹êÀ¦¥®¨à¥un¦Y±o¥¿±`¡BºÎ±o»²¢¡A¤Q¤§¤K¤E³£¬O°·±dªºÄ_Ä_¡C ¦Ó¦pªG¬O¤@Ó¦~¬ö¸û¤jªº¤pªB¤ÍºÎı®É·|¥´©I«Kn¦Ò¼{¨ì¦b»óµÄ©Î«|³ï¦³³¡¤Àªý¶ë¡A·íµM©I§l¤£¶¶ºZ¦ÛµM·|µo¥XÁnµ¡C³Ì±`¨£ªºì¦]«K¬O©Ò¿×ªº·P«_¡AµM¦Ó³oÃþªº¯f¬r·P¬V©Ò³y¦¨ªº¥´©IÀ³¤£·|«ùÄò¤Ó¤[¡AÀHµÛ·P«_»ó¶ëªº¯gª¬¸Ñ°£²zÀ³®ø¥¢¡C¦pªG¨S¦³·P«_¦ýªø´Á¦³»ó¶ë©ÎºÎı¥´©Iªº±¡§Î«Kn¦Ò¼{¨ä¥Lì¦]¡C¹L±ÓˬO¨ä¤¤±`¨£ªº¦]¯À¡C¦]¬°»ó¤lªº¹L±Ó¤ÏÀ³·|¼W¥[¤Àªcª«¡A¤]·|¨Ï»óÂH½¤¸~º¦¦Ó¼vÅT©I§l¹Dªº¶¶ºZ¡A·íµM´N·|¥´©I¤F¡C ¹L±Ó¯gª¬ªº²£¥Í©¹©¹¬O´`§Çº¥ªñªº¡A·s¥Í¨à¨Ã¤£·|¤@¥X¥Í«K¶}©l¦³®ð³Ý¯gª¬¡A§Y«K¬Oªí²{¥X©I§l«æ«P¬Æ¦Ü»´·L³Ý»ïÁn¤]¤£·|°¨¤W¦Ò¼{¦³®ð³Ý¯f¡CÀ¦¥®¨à¹L±Ó¯g©¹©¹¬O¥H¥Ö½§ªº¹L±Óªí²{¬°¥ý¡A©¹©¹·|¦bÁy¤W¡B¥|ªÏ©Î²ä¤lµ¥¸û©ö¥X¦½ªº¦a¤è¥X²{¬õ¯l¡A¤@¯ëºÙ¤§¬°Àã¯l©Î²§¦ì©Ê¥Ö½§ª¢¡Cº¥º¥ªº¥i¯à¦³»ó¤l¹L±Óªº¯gª¬«Kªí²{¥X¨Ó¤F¡A¦p¦¤W°_§É®e©ö¥´¼QÀ¡¡A¦]»ó¤lÄo¦Ó±`¦³´|»ó¤lªº°Ê§@¡A·íµM¤]·|¦]»ó¶ë¦Ó¦³¥´©IÁn¡C¦Ü©ó©I§l¹Dªº¹L±Ó¤ÏÀ³©ÎªÌ»¡¬O®ð³Ý¡A©¹©¹¬O¦b3~4·³º¥º¥²£¥Í©úÅã¯gª¬¡C©Ò¿×ªº¡u¹L±Ó¶i¦æ¦±¡v«K¬O«ü¹L±Ó¯gª¬ªº¶¥¬qÅܤƩʡA¦]¦¹·s¥Í¨à¦³¥´©IÁn¬Æ¦Ü©I§l¦³³Ý»ïÁn¡A¨Ã¤£·|°¨¤W¦Ò¼{¬O®ð³Ý¡CµM¦ÓY¬O¤ÏÂЦ³³Ý»ïÁn¡A¯gª¬¦n¤£®e©öªv¦n¤F¦ý¨S¦h¤[¤S¦³¥t¥~¤@¦¸ªº¯gª¬¡A«Kn¦Ò¼{¬O¥®¨à©Ê®ð³Ý¡CY¥H®ð³Ýªº¤è¦VªvÀø¤´¥¼¨£§ïµ½¡A§ón§ä¨ä¥Lªºì¦]¡A¦pG¹¹D°f¬y©Î¥ý¤Ñ©Ê¤ßŦ¦åºÞªººc³y©Î¨«¦V²§±`¡A³o¨Ç³£»Ýn¶i¤@¨BÀˬd¤~¯à°÷½T©w¡C¹ï©ó¤j¤pªB¤Í¦Ó¨¥¡A®ð³Ý³Ì±`¨£ªºÁ{§Éªí¼x¬°ºC©Ê«y¹Â¡A¦Ó¥B¦±ß¯gª¬¸û©úÅã¡A¤£¤@©wn¦³³Ý»ïÁn¡C¥´©IÁn¥Dnn¨Ó¦Û©ó»óµÄ¤Î³ïÀY¡A³Ý»ïÁn«hµo¦Û©ó®ðºÞ¡A¨âªÌ³£¥i¯à¦bºÎı®É©úÅã¡A¦ý¥NªíªºÁ{§É·N¸q¥ç¤£¦P¡C ÁöµM®ð³Ý¬O¤@ºØ¦h°ò¦]¿ò¶Çªº¯e¯f¡A¦ý¨Ã¤£¬O¤@¥X¥Í«K·|®ð³Ý¡A©M«á¤ÑÀô¹Òªº¼vÅTµ´¹ï¦³³s±aÃö«Y¡C¤@¯ë«D¹L±Ó커µoªº®ð³ÝºÙ¬°¤º¦]«¬®ð³Ý¡A¤]´N¬O¥i¯à·|¦]·P«_©Î¤G¤â·Ïµ¥«D¹L±Ó쪺¦]¯À¦Ó»¤µo¡A©â¦åÀˬd«o´ú¤£¨ì¹L±Ó¤ÏÀ³¡A¦ýÁ{§Éªº¯gª¬ªº½T¬O®ð³Ýªºªí²{¡C¥t¤@ºØ«h¬°¥~¦]«¬®ð³Ý¡A¤]´N¬O·|¦]±µÄ²¨ì¹L±Óì¦Ó»¤µo®ð³Ýªº¯gª¬¡C¥Ñ¦¹¥i¤F¸Ñ®ð³Ýªº¶EÂ_¨Ã«D¾a¥ô¦ó©â¦å©Î¢æ¥úÀˬd¡A³Ì«nªº¤Ï¦Ó¬O¯f¥v¤Î¨Åé²z¾ÇÀˬd¡C¤@¯ë¦Ó¨¥¤º¦]«¬®ð³Ý¬ù¦û¤Q¤À¤§¤@ªº¤ñ¨Ò¡A¤£¹Lµ´¤j³¡¤À³£¬O¥ý¤ÑªºÅé½è¥[«á¤ÑªºÀô¹Ò³y¦¨¡A¨âªÌ¦bªvÀø¤W¤Î¥Í¬¡·ÓÅ@¤W¨ÃµL¤£¦P¡C®ð³ÝÁöµM»P¿ò¶Ç°ò¦]¦³Ãö¡A¦ý¨Ã«D¤÷¥À¥ô¤@¤è¦³®ð³Ý¤~·|¿ò¶Ç¡AÀ³¸Ó»¡¹L±ÓÅé½èªº¿ò¶Ç¡A¦Óªí²{¦b©I§l¹Dªº¹L±Ó¤ÏÀ³«K¬O®ð³Ý¡C¨Ò¦pª¨ª¨ÁöµM¨S¦³®ð³Ý¦ý«o¦³»ó¤l¹L±Óªº¯gª¬¡A¦Ó¤pÄ_Ä_¥i¯à¿ò¶Ç¨ì¹L±ÓÅé½è¦Óªí²{¦b®ðºÞ¡A¦Ó¦¨®ð³Ýªº¯gª¬¡C ¬JµM®ð³Ý·|¦]±µÄ²¥~¦bªº¨ë¿Eª«©Î¹L±Ó커µo¡A¦]¦¹ªvÀøµ´¤£¥u¯à¾aÃĪ«¡A¤]»ÝnÀô¹Òªº°t¦X¡A¥un´î¤Ö¹L±Ó쪺±µÄ²´N¥i¥H´î¤Öµo§@ªº¾÷·|¡C¨ä¹ê¦³¾÷·|§ó¤F¸Ñ®ð³Ý¯f¡A°Ñ»P®ð³Ýªº½Ã±Ð¬¡°Ê¡A¤]«D±`«n¡C³Ì±`¹J¨ìªº«K¬O¹ï®ð³Ý¯f¤@ª¾¥b¸Ñ¦Ó¥¼¯à±µ¨üªø´Á¥B§¹¾ãªºªvÀø¡C¨Ò¦pªvÀø®ð³Ý³Ì«nªºÃÄ«K¬O¡y§l¤J«¬Ãþ©T¾J¡z¡A¤£¹L¤@¯ë¤H¥unÅ¥¨ì¡yÃþ©T¾J¡z3Ó¦r²ö¤£°hÁפTªÙ¡A¤@¤è±®`©ÈÃþ©T¾Jªº°Æ§@¥Î¡A¥t¤@¤è±¤S¥H¬°¯gª¬§ïµ½¤F¨Ï¦Û°Ê°±ÃÄ¡A©Èªø´Á¨Ï¥Î·|¶Ë¨x¶ËµÇ¡C¨ä¹ê¹ï¯e¯f¥»¨¤£¤F¸Ñ¡A¥H¤Î¹ïÃĪ«ªº»~¸Ñ¦Ó¥¼¯à°t¦XÂåÅñ¡A¤Ï¦Ó·|¨Ï®ð³Ý¯gª¬±±¨î¤£Ã©w¡A§ó·|¤ÏÂЬݯf©Î¦YÃÄ¡C¦bÁקK¹L±Óì¤è±¡A¤é±`¥Í¬¡¤WÀ³ª`·N°£Àã¡A±±¨î¬Û¹ïÀã«×¥ª¢´¢¯¢H¨ì¢µ¢¯¢H¤§¶¡¡A¦]¬°¹L±Óì¦p¹Ð蟎©ÎÅðµß³Ì³ßÅw¼éÀ㪺Àô¹Ò¡A¤×¨ä¥xÆW§ó¬OÄÝ©ó¼éÀ㪢¼öªº®ü®q«¬®ðÔ¡A§ó¾A¦X¹L±Óì´þªø¡A°§CÀã«×¤£¶È¥Í¬¡µÎ¾A¤]¥i´î¤Ö¹L±Óì¡C§É³æ¡BªEÀY®M¡A³Q³æµ¥Âæ³¹L±Ó쪺ª««~³Ì¦n¨â¬P´Á´N´«¬~¤@¦¸¡A¬~«á¯M°®©ÎÅΰ®¡C¥t¥~¤G¤âµÒÁö«D¹L±Óì¦ý¬O¥þ¥@¬É¤½»{©ö»¤µo®ð³Ýªº¨ë¿Eª«¡A©Ò¥HÀ³ÁקK§l¤J¡C¦Ü©ó¦b¶¼¹¤è±º«Àç¾i§¡¿Å¡A¤d¸U¤£»Ý¦]®`©È¹L±Ó¦Ó¨î¶¼¹¡A¦~¬ö¶V¤jªº¤pªB¤Í¸zG¹D§ó¦¨¼ô¡A§ó¤£·|¦]¦Y¨ì¬YºØ¹ª«¦Ó»¤µo®ð³Ý¡C¦Ü©ó2·³¥H¤Uªº¤pªB¤Í´Nª`·N¤£nÄá¨ú°íªGÃþ¡A³JÃþµ¥¹L±Óªº¹«~¡A«Ý¸zG¹DÀH¦~ÄÖ¼Wªø¦Ó§ó¦¨¼ô«á¦A²K¥[¡C ®ð³Ýªº¤pªB¤Í¤j¬ù¤K¦¨·|¦X¨Ö¦³¹L±Ó©Ê»óª¢¡A±`¨£ªº¯gª¬«K¬O¦¤W¥´¼QÀ¡¡B´|»ó¤l¡B¬y»ó¤ôµ¥¡C»ó®÷¤£·|ìì¡A«K©¹¤º§l¡A¤[¦Ó¤[¤§«K®e©ö¦X¨Ö¦³»óÄuª¢¡A¦Ó¦³»óÄuª¢Y¤£ªvÀø¦n¤S·|Åý®ð³Ý¤£©ö±±¨î¡A¦]¦¹ªvÀø¤Wn¦P®Éª`·N³o¤T¤è±ªº°ÝÃD¡C¤£¹L¥´©I¬O§_´N¥i¹w´ú¬O§_¦³®ð³ÝˬOn¤£¥²¤Ó´dÆ[¡A¤Ï¦Ó¬O¦Ò¼{¨ì¬O§_¦³¹L±Ó©Ê»óª¢©Î¦X¨Ö»óÄuª¢ªº¯gª¬¡C¥t¥~¡A»ó¤¤»JÅs¦±¡B¹LDµ¥µ¥¤]³£·|¥´©I¡A©Ò¥Hˤ£¥²¥un¤pbaby¤@¦³¥´©IÁn«K¾á¤ß·P«_¤F©Î±N¨Ó·|®ð³Ý¡C¥´©I¬O¤@ºØÁ{§Éªí¼x¡AÀ³n´M§ä¦óºØ¯e¯f¤Þ°_¡CÁöµM¦³¬ã¨sµo²{¥´©I»P®ð³Ý¥i¯à¦³Ãö¡A¦ý¤]¤£¥²¦]¤pªB¤Í·|¥´©I«K¾á¤ß±N¨Ó¦³®ð³Ý¡C²¦³º®ð³Ý¤]¬O¤@ºØ¹L±Ó©Ê¯e¯f¡A©¹©¹·|¦X¨Ö¨ä¥L¹L±Ó¯gª¬¡C½T©w¬O®ð³Ý«h§ó»Ýnªø´Á°t¦X±M¬ìÂå®v±±¨î¯f±¡¡A´N¯f²z¾ÇªºÆ[ÂI¤£¯à»¡®ð³Ý¥i®Úªv¡A¦ýµ´¤j³¡¤À³£¥i¥H±±¨î¨ì¤£»Ý¥ÎÃĤ]¯f±¡Ã©w¡A³Ì»ÝÅU§Òªº¤Ï¦Ó¥¼¯à¤F¸Ñ®ð³Ýªº¥»½è¦Ó¬qÄòªvÀø¡A©¹©¹¨Ï®ð³Ý¯gª¬¤£Ã©w¡C ºK¿ý¦Û¡¨ ¶ý¶ýÄ_Ä_12¤ë¸¹¡¨ ¡@ ¡@ |
||||||
¡@ ªø©°¨àµ£¹L±Ó®ð³Ý·Àã¬ì¥DªvÂå®v ¸°ê°¶
²§¦ì©Ê¥Ö½§ª¢¬O¤@ºØºC©Ê¡A¦Ó¥B·|¤ÏÂеo¥Í¡A©_ÄoµL¤ñªº¥Ö½§ª¢¤ÏÀ³¡C¥¦¬O¤@ºØ¥Ö½§ªº¹L±Ó¤ÏÀ³¡AµM¦Ó¥H¬ì¾ÇªºÆ[ÂI¡A¤S¥i¤À¬°¹L±Ó©Ê(¥~¦]©Ê)ªº¤Î«D¹L±Ó©Ê(¤º¦]©Ê)ªº§ÎºA¡C«eªÌ¤j¬ù¦ô70-85%¡A¥Dn¬O»P¥~¦bªº¹L±Óì¨Ó»¤µo¯e¯fªº¯gª¬¡A¦Ó«áªÌ¬J¦W¬°¤º¦]©Ê¡A¤]´N¬O§ä¤£¥X¯S©wªº¤Þ°_¹L±Óªºì¦]¡A³o³¡¤Àªº¯f¤H¤j¬ù¦ô15-30%¡A¦ýµL½×¨º¤@ºØ«¬ºA¡AÁ{§É¯gª¬Ë¬O¬Û¦Pªº¡C ±Nªñ9¦¨ªº²§¦ì©Ê¥Ö½§ª¢¦b5·³¥H«e«K¶}©l²£¥Í¯gª¬¡AÀHµÛ¦~¬öªº¼Wªø¡A¯gª¬º¥º¥§ïµ½¡CµM¦Ó¥~¦]«¬ªº²§¦ì©Ê¥Ö½§ª¢¡A±N¨Ó¦³3~6¦¨ªº¾÷²v·|µo®i¦¨©I§l¹Dªº±Ó·P©Î®ð³Ý¡A¦Ó¤º¦]«¬ªº²§¦ì©Ê¥Ö½§ª¢¦ý¸û¤£·|¦³¦¹ºtÅÜ¡C
²§¦ì©Ê¥Ö½§ª¢ªº»¤µo¦]¤l ³y¦¨²§¦ì©Ê¥Ö½§ª¢¯gª¬ªºì¦]¨ä¹ê»P°ò¦]¡BÀô¹Ò¤Î§K¬Ì¨t²Î³£¦³³s±aÃö«Y¡A³Ì±`¨£ªº»¤µo¦]¤l²ö¹L©ó¹ª«¡A³J¡B¤û¥¤¡Bªá¥Í¡B¤j¨§¡B³Á¡B³½¤Î°íªG¬O³Ì±`¨£ªº¤CÃþ¹ª«¡A¦ÓªÅ®ð¤¤ªº¹L±Óì¨Ã¤£¬O¥u»P®ð³Ý¦³Ãö¡A´î¤Ö«Ç¤º¹Ð蟎ªº¦s¦b¤]¥i´î»´¯gª¬¡A¦Ü©ó°Êª«ªº¥Ö½§»PÁ½¸µ¥¹L±Óì»P²§¦ì©Ê¥Ö½§ª¢ªº¦]ªGÃö«Y«h»Ý§ó¦hªº¬ì¾ÇÃÒ¾Ú¡A¨ä¥L¤@¨ÇÀô¹Ò¤¤«D¹L±Ó±Ó쪺¨ë¿E¦]¤l¤]·|»¤µo²§¦ì©Ê¥Ö½§ª¢¡C¨Ò¦pªw¼ö¤ô¡B¥Îµæ¥Ê¥¬¨ê¬~¨Åé¡AÁö¦³µu¼È¦³¤îÄoªº·Pı¡A¦ý½T·|¾A±o¨ä¤Ï¡C¬y¦½¤]¬O¤@ºØ¨ë¿E¦]¤l¡A©Ò¥H·íµM«Øij¬ï´Ö½è¡B³z®ðªº¦çªA´î¤Ö³Q¨ë¿Eªº¾÷·|¡C¤ß²z¦]¯À¤]¤£¯à©¿²¤¡A¦³²§¦ì©Ê¥Ö½§ª¢ªº¤pªB¤Í¡A¦]¬°Äo¦ÓºÎ¤£¦n¡A¦]¬°Äo¦Ó¦b±ß¤W¤£¦Ûıªº·kÄo¡A³o¨Ç¤£¶ÈÅý²§¦ì©Ê¥Ö½§ª¢§ó´c¤Æ¡A¤]¦]ºÎ±o¤£¦wæӼvÅT¤é±`ªº¦æ¬°¡CµJ¼{¤ÎÀ£¤Oªº½T·|¨Ï¨Åé¤Àªc§ó¦hªºµoª¢©Î¤Þ°_Äo·Pªºª«½è¡C
²§¦ì©Ê¥Ö½§ª¢ªº³B¸m n§¹¥þ±±¨î²§¦ì©Ê¥Ö½§ª¢»Ýn¦h±¦Vªº³B¸m¡A¥]¬A¥Ö½§«OÀã¡AÃĪ«ªvÀø¥H¤Î¥h°£»¤µo´c¤Æªº¨ë¿Eª«¡C
¥Ö½§«OÀã ²§¦ì©Ê¥Ö½§ª¢ªº¯f¤H¥Ö½§°Ï¯Ê¥F¤F¤@¼h«Ì»Ù¡A§ó®e©ö³y¦¨¤ô¤Àªº¬y¥¢¡A§ó©ö³y¦¨¥Ö½§·L²ÓªºµõÁ_¡A¤]¬O³y¦¨¹L±Óì©Î¨ë¿Eª«©ö«I¤J¤§³B¡C¨ä¹ê¥i¥Î·L·Åªº¤ô®ûªw20¤ÀÄÁ¡A¤§«á¤£n¥Î¤OÀ¿°®¡A¦Ó¬O»´·L©ç°®¡A¦A¶î©Ù«OÀã¨Å²G¡A¥i«O«ù¥Ö½§ªº¤ô¤À¤]¥i×´_¥Ö½§ªº¨¤½è¼h¡C°µ¦n«OÀã¤]¥i¼W¥[¥~¥ÎÃþ©T¾JÃÄ»I§l¦¬ªº®ÄªG¡C¹ï©ó·¥ÄY«ªº³¡¦ì¥i¨Ï¥ÎÀ㯽¥¬Âл\«ùÄò«OÀã¡A¨Ã¶î¤W«OÀã¨Å²G¡C
Ãþ©T¾JÃÄ»I ¨ä¹êÃþ©T¾J¤@ª½¬O«D±`«nªº§Üµo¨¥ÃĪ«¡A¥u¬OI¤W¤FÃþ©T¾Jªº²±¦W¤§²Ö¡A¦Ó¨Ï¤j²³»Dª¾¦âÅÜ¡CÃþ©T¾JÃÄ»I°£¤FªvÀø«æ©Ê´Áªº¥Ö½§¯gª¬¡A¦³¨Ç·sªº¬ã¨s¤]«Ø¤@¬P´Á¨â¦¸¶î©Ù¦b¦nµoÀã¯lªº³¡¦ì¤]¥i¹F¨ìªø´Á±±¨îªº¥Øªº¡CÃþ©T¾JÃÄ»I¤@±j«×¥i¤À¤CÓµ¥¯Å¡A°£¤F¦³¨Ç³¡¦ì¤wºC©ÊaÅ~¤Æ¥i¥Î¸û±jªº§½³¡Ãþ©T¾JÃÄ»I¡Aªø´Á¦Ó¨¥ÁÙ¬On¾a«OÀã¤Î§C±j«×ªºÃþ©T¾JÃÄ»I¨Óºû«ùªvÀø¡C
µL¥i±ÏÃĪºÄo ²³æªº»¡Â²³æªº»¡¥un±±¨î¥Ö½§ªºµoª¢´N¥i±±¨î¾iªº·Pı¡A¤£¹LªÌ¥u¬O¯È¤W½Í§L¡C¯f¤H©¹©¹´N¬OÄo¦Ó¤£¦Û¥Dªº·k§ì¦Ó¨Ï²§¦ì©Ê¥Ö½§ª¢§ó´c¤Æ¡C§Ü²Õ´Ói¬O³Ì±`¥Îªº¤îÄoÃĪ«¡A¤£¹L²Õ´Ói¥u¬O³y¦¨¥Ö½§Äoªº¤p³¡¥÷¦]¯À¡A¦]¦¹¨Ï¥Î§Ü²Õ´Ói¨Ã¤£¤@©w¦³®Ä±±¨îÄoªº·Pı¡A¦³®É¤Ï¦Ó¬O§Q¥Î¨äÂíÀRªº°Æ§@¥Î¨Ó¹F¨ì¤îÄoªº®ÄªG¡C¦Ó·s¤@¥Nªºªø®Ä§Ü²Õ´Ói¨Ã¤£¤@©w´N¤ñ¸û¦³®Ä¡C¥Ñ©óÄo·P©¹©¹¦b±ß¤W¸û©úÅã¡A©Ò¥H¦bºÎ«e¥i¿ï¥Î©ö³y¦¨¶ÝºÎªº²Ä¤@¥N§Ü²Õ´ÓiªA¥Î¡C¦Ü©ó®ÄªG¤´¤£¨ÎªÌ¡A¥i¨Ï¥Î¦pdoxepinªº»´·L§Ü¼~Æ{¾¯¦P®É¤]¦³§Ü²Õ´Óiªº®ÄªG¡C
ÁקK±µÄ²¹L±Óì Àô¹Òªº±±¨î¨ÓÁקKªÅ®ð¤¤ªº¹L±Óì¤]¬O¥þ¤è¦ìªvÀø²§¦ì©Ê¥Ö½§ª¢«nªº¤@Àô¡A³o¨Ç§ïµ½¹L±Ó쪺¤è¦¡³£¬O¦Ñ¥Í±`½Í¡C³\¦h¯f¤H¤]®Ú¾Ú«Øij´«¤F¨¾蟎¹ì¨ã¡A¥Î¤F°£Àã¾÷¡BªÅ®ð²M²b¾÷µ¥µ¥¡A¤]¾¨¶q¤£¥Î¥¬»s«~ªº®a¹¢¡A¦ý¯gª¬«o¤£¨£§ïµ½¡C¦ý¾Ú²Îp¡A¥u¦³10%ªº¯f¤H·|§¹¥þ¨Ì·Ó«Øij¨ÓÁקK¹L±Óì¡A²¦³ºn«ùÄò´î¤Ö¹L±Óì¡A¤£¶Èªá¿ú¶O®É¡A¦P®É§ïÅܤF§Ú̪º¥Í¬¡«¬ºA¡A¦ý½T¦³«Ü¦h¬ã¨sÃÒ¾ÚÅã¥Ü¨ä»P²§¦ì©Ê¥Ö½§ª¢¦³³s±aÃö«Y¡A§ä¥X»¤µo¦]¤l¥u¬OÓ°_ÂI¡A«ùÄòªº½Ã¥Í±Ð¨|§ó»Ý¥[§â«l¡C
¥Ö½§·P¬V ²§¦ì©Ê¥Ö½§ª¢ªº¥Ö½§¤W±`·|¦³ª÷¶À¦â¸²µå²yµß·P¬V¡A¦Óª÷¶À¦â¸²µå²yµß·|²£¥Í¶W§Üì§ó©ö»P¥Ö½§²ÓMµ²¦X¦Ó³y¦¨¯gª¬´c¤Æ¡C¥²n®É©Î¥Ö½§¦³²Óµß·P¬V®ÉÀ³°t¦X¨Ï¥Î¹ï§Üª÷¶À¦â¸²µå²yµßªº§Ü¥Í¯À¡A§½³¡·P¬V¤]¥i¥Î§Ü¥Í¯ÀÃÄ»I¶î©Ù¡C¥t¥~²§¦ì©Ê¥Ö½§ª¢ªº¥Ö½§¤]·|¨ü¯f¬r¦p疱¯l¯f¬rªº·P¬V¡C¦Ó³y¦¨Äjº©©Ê©_Äoªº¤p¤ôªw¡A³o¨Ç¤p¤ôªw¬Æ¦Ü·|¥X¼g³o¨Ç¤p¤ôªw¬Æ¦Ü·|¥X¦å¡Aµ²¯m¡C¦³®É¤]·|³Q»~»{¬°¬Oª÷¶À¦â¸²µå²yµßªº·P¬V¡CYÃhºÃ¬°疱¯l¯f¬r·P¬V¡A¥i¼È°±§½³¡Ãþ©T¾JÃÄ»I¡A¨Ã¶}©l¥Î§Ü¯f¬rÃĪ«¡C
·sªºÀÆ¥ú ªø´Á¥H¨Ó¹ï©ó²§¦ì©Ê¥Ö½§ª¢¨S¦³§ó¦³®Ä¡A§ó·sªºªvÀø¤è¦¡¡CÃø±o¦b«e´X¦~¸g¥Ñ¦h¦~ªºÁ{§É¸ÕÅçµ²ªG¡A²×©ó¦³·sªº«DÃþ©T¾J¡A±MªùªvÀø²§¦ì©Ê¥Ö½§ª¢ªºÃÄ»I¤W¥«¡A¤@¬°¡y´¶¯S¥Ö¡z¡A¤@¬°¡yÂå¥ß§´¡z¡C³oÃþÃÄ»I¦Ü¤Ö¦w¥þ¡A¨Ã¤£·|¦pÃþ©T¾JÃÄ»I³y¦¨¥Ö½§ÅÜÁ¡©Î¥þ¨§l¦¬¡A¦Ó¥B¦³¹êÃÒÅã¥Ü¨äÁ{§É®ÄªG¡C³ø§iÅã¥Ü¨Ï¥Î¤T¤Ñªº´¶¯S¥Ö«K¥i´î¤ÖÄo·P¡A¥u¬Oè¥Î®É¥Ö½§¦³µy·L¨`¼ö·P¡A¤@¬P´Á«K·|®ø¥¢¡A¤d¸U¤£n¦]¦¹¦Ó°±¤î¥ÎÃÄ¡C
¹ï©ó²§¦ì©Ê¥Ö½§ª¢¡A«OÀã¬Oµ´¹ïªº»Ýn¡A¹ïÃþ©T¾JÃÄ»I¤£¥²¦]¤£ª¾¦Ó®£·W¡A¦Ó¬O§óÁA¸Ñ³oÃþªºÃĪ«¡C¹ï©ó·sªºÃĪ«¤£¥u´Á«Ý¡A§ónÁA¸Ñ¤ÎÆ[¹î¡A¦ý¤]§O§Ñ¤F¿í´`¶Ç²Îªº«ØijªvÀø¡C ºK¿ý¦Û¡¨°·±d¥@¬É¡¨ ¡@ |
||||||
ªø©°¨àµ£Âå°| ¨àµ£¹L±Ó®ð³Ý·Àã¬ì ¸°ê°¶Âå®v ±`Å¥»¡¤pªB¤Í¹ï®a¹Ð¹L±Ó¡A¦Ó©Ò¿×ªº®a¹Ð¨Ã«D«ü±q«Ç¥~¸¶i«Î¤ºªº¦Ç¹Ð¡A¦Ó¬O«ü·½¦Û©ó®a¤¤ªº¥Î«~²æ¸¨©Î¤À¸Ñ«á©Ò²£¥Íªº·¥·L²Óªº¹Ð®J¡C®a¹Ðªº¦¨¤À¥]¬A¤H©ÎÃdª«ªº¥Ö½§²æ¸¨ªº¥Ö®h¡AÅðµß¡AÁôÂéó§É³æ¡B§É¹Ô¤¤ªº¹Ð蟎µ¥¡A¨ä¤¤ªº¹Ð蟎§ó¬O³y¦¨¥xÆW¨àµ£¹L±Ó¯gª¬¥]¬A®ð³Ý¡B¹L±Ó©Ê»óª¢µ¥ªººn¦]¯À¡CªvÀø¹L±Ó¯g¤£¥u¬O¾aÃĪ«ªº§@¥Î¡AÀô¹Òªº±±¨îµ´¹ï¬O«D±`«nªº¤@Àô¡A¥²¶·¬Û»²¬Û¦¨¤~¯à¦³®Ä±±¨î¯gª¬¡C´î¤Ö¹L±Ó쪺¨ë¿Eªº¾÷·|¡A¦ÛµM´î¤Ö¹L±Ó¯gª¬ªº²£¥Í¡C »Ýn¥ÎªÅ®ð²M²b¾÷©Î¬O°£Àã¾÷¡H ¹Ð蟎³Ì³ßÅw¼éÀã·Å·xªºÀô¹Ò¡An¥h°£¹Ð蟎À³¿ï¾Ü°£Àã¾÷¡C±N«Ç¤ºªºÀã«×±±¨î¦b¬Û¹ïÀã«×50%¦Ü60%¤§¶¡¡A¬J¤£·|¤Ó°®Àê¦Ó·P¨ì¤£¾A¡A¤S¥i´î¤Ö¹Ð蟎¤ÎÅðµßªº¦s¦b¡C¥Ñ©ó¹Ð蟎ªº«¶q¸û¯»¹Ð¥Ö®h¬°«¡A°£«D²M±½©Ð¶¡¡A§_«h¤@¯ë¦b«Ç¤ºÀR¤îªºªÅ®ð¤¤¹Ð蟎¨Ã¤£·|¨ì³B¸´¡A¦]¦¹ªÅ®ð²M²b¾÷¨Ã¤£¯à®É®Éµo´§¨ä¥h°£¹Ð蟎ªº¥\¥Î¡C¤£¹L¨ä¹ï¥h°£¤G¤â·Ï¡A²§¨ý©ÎÃdª«¥Ö®hªº¹L±Óìµ¥·|¤Þ°_®ð³Ýªº¨ë¿Eª«¬O¦³À°§Uªº¡C ¨Ï¥Î¼ö¤ô¬~¦ç¡H ¹Ð蟎¥H¤Hªº¥Ö®h¬°¹¡A¦]¦¹³Q³æ¡AªEÀY®M¡A§É¹Ôµ¥»P¤HÅ鱵IJ¦hªº¦a¤è¦ÛµM¹Ð蟎ªº¼Æ¶q«K¦h¡C¦]¬°¥Î¤@¯ë§N¤ô¬~¦ç¨ÃµLªk®ø°£¹Ð蟎¡A©Ò¥H«Øij¨C¹j¤@¦Ü¤G¶g¥i¥Î¬ùÄá¤ó60«×ªº¼ö¤ô²M¬~§É³æ¡BªEÀY®M¡CµM¦Ó¦b¥xÆWªº¬~¦ç¾÷«Ü¤Ö¥i¥Hª½±µ±±¨î¬~¦ç·Å«×¡A¦]¦¹¬~«á¦Ü¤Ö¥Î¯M°®¾÷¯M°®¤G¤Q¤ÀÄÁ©Î¬O¦b¶§¥ú¤U´½°®¥ç¥i¹F¨ì±þ¦º¹Ð蟎ªº¥Øªº¡C ¨Ï¥Î¨¾蟎§É¸n¡H §É¹Ô¤£©ö²M¬~¡A¦Ó§É¹Ô²`¼h¤]·|ÁôÂäj¶qªº¹L±Óì¡A¨¾蟎§É¸n¡AªEÀY®Mµ¥¤´¬O¤@Ó¦³®Ä¥B²³æªº¤èªk¨Ó´î¤Ö¹Ð蟎ªºÄÆ´»P±µÄ²¡A¥u¬O¥þ®M¶R¤U¨Ó¥i¬O¤@¤ñ¤£¤pªºt¾á¡CÀHµÛ¨¾蟎§ÜµßªºÆ[©À¤é¯q²`ȤH¤ß¡A³oÃþªº°Ó«~«K¤j¶q¥R¥¸©ó¼s§i¤¤¡A¥u¬O¬O§_¯uªº¨ã¦³©Ò¼Ðº]ªº¨¾蟎®ÄªG¡A©óÁʶR®É§óÀ³ÂÔ·V¤ñ¸û¡An½T©w¦³«~µP¥B«HÅA¨Îªº¼t°Ó¡CY«Ç¥~ªÅ¶¡³\¥i¥ç¥i¦b¶§¥ú¤UÃnÅΧɹԡC µ²½× ÁöµM®É®É¨è¨èª`·N®a¤¤Àô¹Ò±±¨î¹ï©ó¤u§@¦£¸Lªº®aªø¬O«D±`¨¯Wªº¡A¦ý¤F¸Ñ¹L±Óì¡A°µ¦nÀô¹Ò±±¨î¨ÓÁקK¹L±Ó챵IJ½T¬OªvÀø¹L±Ó©Ê¯e¯f¤Î®ð³Ýªº²Ä¤@¨B¡C°£¤FÀô¹Ò±±¨î¥~¡A§ón»P¨àµ£¹L±Ó¬ìÂå®v¤@¦P°Q½×ÃĪ«ªº¨Ï¥Î¤ÎªvÀøªº¤è¦V¡CªvÀø¹L±Ó¯e¯f¬O»Ýn®É¶¡»P@¤ßªº¡A¥þ®a°Êû¤@¦P²M²z¦Û¤vªº©~®aÀô¹Ò¡A¤]Åý¥þ®a¤H©I§lªº§ó¦n¡A§ó°·±d¡C ¡@ |
||||||
¡@
®Ú¾Úªø©°¨àµ£Âå°|91¦~ªº¬ã¨s³ø§iÅã¥Ü¡A¥x¥_¥«°ê¤p¨àµ£ªº®ð³Ý²±¦æ²v¤w¼W¥[¨ì19.8%¡A¬Û¸û©ó30¦~«eªº¼Æ¾Ú¡A¨¬¨¬¼W¥[¤F15¿¡C·íµM¨Ã«D©Ò¦³©I§l®ÉÅ¥¨ì¦³«¦«¦ªº³Ý»ïÁn«K¬O®ð³Ý¡A¦]¬°³¡¤Àªº®ðºÞª¢©ÎªÍª¢¤]·|¦³Ãþ¦ü±o¯gª¬¡A¤]¤£¬O¦p¤@¯ëªº¨èªO¦L¶H¤@©wn³Ý¨ì©I§l§xÃø®É¤~ºâ¬O®ð³Ý¡C¬Û¤Ï¦a¡A®ð³Ý³Ì±`¨£ªº¯gª¬Ë¬O¤ÏÂÐ¥BºC©Êªº«y¹Â¡C¤@¯ë©Ò¿×¡§·P«_¡¨¬O«ü©I§l¹Dªº¯f¬r·P¬V¡A§Y¨Ï¤£ªvÀø¦b¤@¨â¶g¤º¤]·|¦ÛµM²¬Â¡¡C¦ýY¬O¨C¦¸¡§·P«_¡¨ªº¯gª¬«ùÄò¼Æ¶g¡A¹j¨S¦h¤[©Î¤Ñ®ð¤@Âà²D«K¤S¡§·P«_¡¨¤F¡A©Î¬O¬¡°Ê«á«K®e©ö«y¹Â¥B¦±ß«y±o¸û©úÅã¡A³o¨Ã¤£¥Nªí¤pªB¤Í©è§Ü¤O®t¡A¨ä¹ê«Kn¦Ò¼{®ð³Ýªº¥i¯à©Ê¡C |
||||||
ªL¤fªø©°¨àµ£Âå°|¨àµ£¹L±Ó®ð³Ý§K¬Ì·Àã¬ì ¸°ê°¶¥DªvÂå®v ®ð³ÝÄÝ©ó¤@ºØºC©Ê®ð¹Dª¢¯g¡A«æ©Êµo§@®É·|¦³³Ý»ï¡B©I§l§xÃø¡B¯Ý´e¥H¤Î«y¹Âµ¥¯gª¬¡A¦ý³Ì±`¨£ªºÁ{§Éªí²{¬O¤Ï¦Ó¬OºC©Ê¤Î¤ÏÂЫy¹Â¡C®ð³ÝÃĪ«ªºªvÀø¥Øªº§Y¦b©ó«ì´_¨Ã¥BÁקK®ð³Ý¯gª¬ªº²£¥Í©M©I§l¹D®ð¬yªý¶ë¡A¥i¤À¬°«æ©Êµo§@®Éªº½w¸ÑÃĪ«¤Îªø´Á¨Ï¥Îªº±±¨îÃĪ«¨â¤jÃþ¡G ¡P ½w¸ÑÃĪ«¡]«æ±ÏÃĪ«¡^¡G¥Hµu®Ä«¬¤ä®ðºÞÂX±i¾¯¬°¥D¡AÃĪ«§@¥Î§Ö®ÄªG¨Î¡A¦b®ð³Ý«æ©Êµo§@®É¡A¥i¥H¨³³t½w¸Ñ¤ä®ðºÞ¦¬ÁY¤Î©I§l§xÃø¡B«y¹Â¡B©M³Ý»ïµ¥¯gª¬¡C¦¹ÃþÃĪ«¥H³t®Ä«¬§l¤J¦¡£]2¥æ·P¯«¸g¿³¾Ä¾¯¬°¥D¡B¨ä¥L¥]§t¤fªA©Îª`®g¯ùÆP»s¾¯¡B§l¤J¦¡§Ü¤AñQÁxÆP¾¯¡]ipratropium¡^µ¥¡C ¡P ±±¨îÃĪ«¡]¹w¨¾ÃĪ«¡^¡G¥H§Üµoª¢ÃĪ«¬°¥D¡A¥Î©óªø´Á±±¨î®ð³Ý¯f±¡¡A¹w¨¾®ð³Ý´c¤Æ¥H¤Î«O¾i®ðºÞ¡A¥²¶·¨C¤é«ùÄò¨Ï¥Î¡C§Üµoª¢ÃĪ«¤¤³Ì«n¬°§l¤J©ÊÃþ©T¾J¡AÃþ©T¾J¥H§l¤J¾¹§l¤J«áª½±µ§@¥Î¦b©I§l¹D¡A¥þ¨©Êªº°Æ§@¥Î«D±`¤Ö¡A¬O¥Ø«e¬°¤î³Ì¦³®Äªº§Ü®ð³ÝÃĪ«¡C±±¨îÃĪ«ÁÙ¥]¬Aªø®Ä«¬¤ä®ðºÞÂX±i¾¯¡B¤fªA½wÄÀ«¬¯ùÆP»s¾¯¡B¥Õ¤T²m¯À«ú§Ü¾¯¡]leukotriene¡^µ¥¡A¥i»²§U§l¤J©ÊÃþ©T¾J¦@¦P¨Ï¥Î¥[±jÀø®Ä¡A´î¤Ö°Æ§@¥Îªº²£¥Í¡C¨ä¤¤¯ùÆP¡]Theophylline¡^ªº»ù®æ«K©y¦ý°Æ§@¥Î¸û¦h¡F¥Õ¤T²m¯À«ú§Ü¾¯¬O·s¤@Ãþªº¤fªA®ð³ÝÃĪ«¡A§Üµoª¢®ÄªG¤ñÃþ©T¾J®z¡A¥Dn¥Î©óªvÀø»´¤¤«×®ð³Ý¡C¦Ü©óªø®Ä«¬¤ä®ðºÞÂX±i¾¯¨Ã¤£«Øij³æ¿W¨Ï¥Î¡A¦X¨Ö§l¤J©ÊÃþ©T¾J¥iµo´§§ó¤jªºÀø®Ä¡C
®ð³Ý±±¨îÁͶաЦX¨Ö¦¡Àøªk ¥Ø«e¥xÆWªvÀø®ð³Ýªº¤è¦¡³q±`±Ä¶¥±è¦¡Àøªk¡A±N®ð³Ý¨ÌÄY««×¤À¬°¥|Ó¶¥¬q¡A²Ä¤@¶¥¦Û²Ä¥|¶¥¨Ì§Ç¬°¶¡·²µo§@©Ê®ð³Ý¡B»´«×«ùÄò©Ê®ð³Ý¡B¤¤«×«ùÄò©Ê®ð³Ý¥H¤Î««×«ùÄò©Ê®ð³Ý¡A¨C¤@¶¥¬q«Øij³B¸mªºÃĪ«ºØÃþ»P¾¯¶q¤]·|ÀH¤§½Õ¾ã¡C·í¯f±w¦b¬YÓ¶¥¬q®É®ð³Ý±±¨î¤£¦n¡A§Y¥i¤É¶¥¶i¤J¤U¤@¶¥¡A¤Ï¤§¡AY®ð³Ý±o¨ì±±¨î¨Ã¥Bºû«ù¦Ü¤Ö¤TÓ¤ë¥H¤W¡A´N¥i¥H°¶¥¨ì¤U¤@¶¥¡A³vº¥´î¤ÖÃĪ«ºØÃþ©Î¾¯¶q¡C ªñ¦~¨Ó®ð³Ý±±¨î¤§ÁͶդw´Â¦V¦X¨Ö¦¡Àøªk¡A©Ò¿×¦X¨Ö¦¡Àøªk«üªº¬O¦X¨Ö¨Ï¥Îªø®Ä§l¤J«¬£]2¥æ·P¿³¾Ä¾¯»P§C¾¯¶q§l¤J«¬Ãþ©T¾J¡A¨ã¦³«ù¤[©Ê®ðºÞÂX±i»P§Üµoª¢ªº¥[¦¨ªvÀø®ÄªG¡A¦bªø´Á°lÂܯf¤HªºªÍ¥\¯à©Î®p³tȬҦ³©úÅã§ïµ½¡C
¦X¨Ö¦¡Àøªk¥i´î¤ÖÃþ©T¾J¥Î¶q ¦X¨Ö¦¡Àøªkªº³Ì¤j¦n³B¡A§Y¦b©ó¥i¥H´î¤ÖÃþ©T¾Jªº¨Ï¥Î¾¯¶q¡C¾¨ºÞ§l¤J©ÊÃþ©T¾Jªº°Æ§@¥Î·¥¤Ö¡A¦ý¤´¦³³\¦h¤H¹ïÃþ©T¾J·P¨ì¼~¼{¡A¦Ó¦b¯fªp¸û¬°ÄY«ªº®ð³Ý±wªÌ¡A¶i¶¥ªvÀø®É©Ò¨Ï¥ÎªºÃþ©T¾J¾¯¶q¤ñ¸û°ª¡A¬Û¹ï¨Ó»¡²£¥Í°Æ§@¥Îªº¾÷·|¤]¸û¤j¡C®Ú¾ÚÁ{§É¬ã¨s³ø§iÅã¥Ü¡A§C¾¯¶qªº§l¤J¦¡Ãþ©T¾J¥[¤Wªø®Ä«¬ÂX±i¾¯ªºÀø®Ä¡A¤ñ³æ¿W¨Ï¥Î°ª¾¯¶qªº§l¤J¦¡Ãþ©T¾J§ó¬°ÅãµÛ¡A¥ç§Y¦X¨Ö¦¡Àøªk§ïµ½®ð³Ýªº®ÄªGÀu©ó¤GºØÃÄÓ§O¨Ï¥Î¡C¦]¦¹¦b¥Ø«e®ð³Ý¶EÀø«ü¤Þ¤¤¡A¦X¨Ö¦¡Àøªk¤w¬O¤¤¡B««×®ð³Ý±±¨îªº«Øijº¿ïÃĪ«³B¤è¡A¦Ü©ó»´«×®ð³Ýªº±±¨î¡A«h¤´¥H§l¤J©ÊÃþ©T¾J¬°¥D¡C
®ð³ÝªvÀø·sÀÆ¥ú ®ð³Ý¬O¤@ºØ¹L±Ó¤ÏÀ³¡A¤j³¡¤À®ð³Ý¯f±wÅ餺ªºIgE§ÜÅé¼Æ¶q·|¤É°ª¡A§ÜIgE§ÜÅéÀøªk(Anti-immunoglobulin E)§Y¬O°w¹ï¹L¦hªºIgE§ÜÅé§@¬°ªvÀø¼Ðªº¡A§Q¥Î¤H¤u¦X¦¨ªº§ÜIgE§ÜÅé¥Hª`®g¤è¦¡¥´¤J¥Ö¤U¡A±NÅ餺´åÂ÷ªºIgE§ÜÅé«ú§Ü¦í¡AIgE§ÜÅé«K¤£·|©MªÎ¤j²ÓMµ²¦X²£¥Í¶i¤@¨Bªºµoª¢¤ÏÀ³¡A¦b®ð³Ý¯gª¬ªº¤ÏÀ³¤W´å«K²×¤î¦í¡C³oºØÀøªk¥iÂkÃþ¬°§K¬ÌÀøªkªº¤@ºØ¡A³Ìªñ5¡B6¦~¨Ó°ê¥~¤w¦³¤£¤ÖÁ{§É¬ã¨s³ø§i¡A¹êÅçµo²{®ð³Ý±wªÌ¡]¥]§t¦¨¤H»P¨àµ£®ð³Ý±wªÌ¡^¸g¥Ö¤Uª`®gªvÀø«á¡AÅ餺IgE§ÜÅ骺§t¶q¦b¤@¤Ñ¤§¤º§YÅãµÛ¤U°¡A¸g¹L¼ÆÓ¤ë«áªº°lÂÜÆ[¹î¡A¤]µo²{¨ì±wªÌªº®ð³Ý¯gª¬Àò±o§ïµ½¡C §ÜIgE§ÜÅéÀøªk¦b¤µ¦~¡]2003¦~¡^3¤ë¤wÀò±o¬ü°êFDA®Öã³q¹L¡A¥i¹w´Á¦¹ÀøªkÀ³¥Î©óÁ{§ÉªvÀø±N¬O«ü¤é¥i«Ý¡C¸û¬°¥i±¤ªº¬O¡A°ê¤º¹ï©ó§ÜIgE§ÜÅéÀøªkªº¬ã¨s¸}¨B¸ûºC¡A¥Ø«e©|µL©M°ê¥~¦P¨BªºÁ{§É¹êÅç¡A°ê¤º®ð³Ý±wªÌ¥i¯àÁٻݦAµ¥¤@µ¥¡C¦Ó¦b·sªºªvÀø¥¼¦¨¼ô«e¡A«ez¦X¨ÖªvÀøÀ³¬O²{¶¥¬qªvÀø®ð³Ý³Ì«n¥B³Ì¨Îªº¤è¦¡¡C
®ð³Ý½Ã±Ð¤´»Ý¥[±j ¨ì¥Ø«e¬°¤î¡AÃþ©T¾J¬OªvÀø®ð³Ý§Üµoª¢ÃĪ«¤¤³Ì¦³®Äªº¿ï¾Ü¡C¦ý¤@¯ë¥Á²³¦]¬°¹ïÃþ©T¾Jªº¤£¤F¸Ñ»P¿ù»~ªº¨èª©¦L¶H¡A¦Ó®`©È¨Ï¥ÎÃþ©T¾J¡C®ð³ÝªvÀø³q±`»Ýn¼Æ¤ë¬Æ¦Ü¼Æ¦~¡A³¡¤À±wªÌ¦]¬°¾á¤ßÃþ©T¾J·|¦³°Æ§@¥Î¡A¨Ï¥ÎÃþ©T¾J¤@¬q®É¶¡¯gª¬§ïµ½«á§Y¦Û¦æ½Õ¾ã¾¯¶q¬Æ¦Ü°±ÃÄ¡A¤Ï¦Óªýê¤F®ð³ÝªºªvÀø¡C¦]¦¹¡AÁٻݦA¥[±j±Ð¨|®ð³Ý±wªÌ¤Î¨ä®aÄÝ¡A¹ï©ó§l¤J©ÊÃþ©T¾J©ê«ù¥¿±ªººA«×¡A¥un¿í·ÓÂåÅñ¥¿½T¨Ï¥Î¡AÃþ©T¾JªvÀø®ð³Ýªº®ÄªGµ´¹ï¬O§Q¦h©ó¹ú¡C¦¹¥~¡A®ð³ÝÃĪ«ªº§l¤J§Þ¥©¤]¶·¯S§Oª`·N¬O§_¥¿½T¡A¤×¨ä¬O¹ï©ó¨àµ£±wªÌ¡C®Ú¾Ú½Õ¬d¡A¥_¥«®ð³Ý¾Çµ£¦Ü¤Ö¦³¥b¼Æ¥H¤W¨Ï¥Î§l¤J©Ê®ð³ÝÃĪ«ªº¤è¦¡¤£¥¿½T¡A¨Ï±o¹w´ÁªvÀøªº®ÄªG¥´§é¦©¡C ¦p¦ó¨Ï®ð³Ý¥ÎÃĵo´§³Ì¨Î¥\®Ä¡A®ð³Ý½Ã±Ð§êºt¬Û·í«nªº¨¤¦â¡CÂå®v°£¤F¿í·Ó®ð³Ý¶EÀø«ü¤Þ¡A¨î©w¨C¦ì±wªÌªºÓ¤HªvÀøp¹º¡A«ü¾É±wªÌ¨Ì¾Ú¤£¦P¯gª¬©ÎºÊ´úµ²ªG½Õ¾ã¨Ï¥Î¤£¦PªºÃĪ«»P¾¯¶q¨Ó¶i¦æªvÀø¤§¥~¡A¤]À³Åý¨C¦ì¯f±w±µ¨ü§¹¾ãªº®ð³Ý±Ð¨|¡A±Ð¾É¯f±w¦p¦óÁקK¹L±Óì¡A«ü¾É¯f±w¥¿½T¨Ï¥Î§l¤JÃĪ«ªº¤è¦¡¥H¤Î¨Ï¥Î®É¾÷¡AÅý±wªÌ¹ï®ð³ÝÃĪ«¤Î§l¤J¾¹¨ã§ó¥[ÁA¸Ñ¡A¥H¤Î±wªÌ¥»¨»P¨ä®aÄݦb¤é±`¥Í¬¡¤W¦p¦ó³B²z®ð³Ý°ÝÃD¡C¹ï©ó®ð³ÝªºªvÀø»P¹w¨¾¡AÂå®vªº³d¥ô¤£¶È¤î©ó¶}ÃĪvÀø¦Ó¤w¡A§ó§Æ±æ¯à°÷³z¹L½Ã±Ð¡A¥þ¤è¦ìªº·ÓÅU®ð³Ý¯f±w¡C ¡@ ¡@ |
||||||
ªø©°¨àµ£Âå°|¨àµ£¹L±Ó®ð³Ý·Àã¬ì ¸°ê°¶Âå®v
¤Q¦hÓ¤p®Éªº¸¦æ¡A°£¤F¬¡°Ê¥²»Ý¨î©ó¤T¸Uù°ªªÅ¤¤ªºÅK³¾¤º¡A¤ß±¡Ë¨S¦³¦]¦¹¦Ó»·ÃG¡AË°¸º¸³Q¶Ã¬yÅͱo¤ßªiÀúºy¡A³s¸¨¦a«á¤]¨S¦³½ñ¹êªº·Pı¡C¨Ó±µ¾÷ªº¤H¦¤w¦w±Æ¦n¡A¥u¤£¹L¤£¬O·Q¹³¤¤ªº^°ê²Ô¤h¡A¦Ó¬O¨µÛµum¾ÞµÛ±aµÛµÄ½Õªº^»yªºD¤p¤l¡A¤@¸ôÅX¨®¥Ñ§Æ´µÃ¹¾÷³õ¦Ü«n¦w´¶¹y¤pÂí¡C¤@¼Ëªº¤Ó¶§¡A¥u¬O¨B½Õ¤]¤ñ¸ûºC¨Ç¡A±ß¤W¤KÂI¦h¤´²²ÅÊ©ó¦a¥½u¤W¡A¹ê¦b¤£´±¬Û«H¦Û¤v¤w½ñ¤W¤@Ó¸¹ºÙ¤é¤£¸¨ªº°ê®a¡C ²Ä¤@¦¸¨«¶iÂå°|±JªÙ¯U¹iªº¨«´Y¡A¤ì½è¦aªO³Q«p«ªº¦æ§õÀ£±o¨Ì§r§@ÅT¡A¨¾¤õªù¼h¼hªºªý¹j§ó§Î¤o¨BÃø²¾¡AªÅ®ð¤¤Äjº©µÛ¥j¦Ñ«Ø¿v¯S¦³ªº¾`¨ý¡CÂ÷¶}ª«½è¨ú¦V¥Í¬¡«K§Qªº¥x¥_¡A¦í¶i³o¤@¶¡¨S¦³¹q¸Ü¡B¦¬µ¾÷¤Î¹qµø¾÷ªº³æ¨±JªÙ¡C¤@±i®Ñ®à¡B¤@Ó¦çÃo¡B¤@®u³æ¤H§É«Øºc¤F¤@¤H¥@¬É¡C²¦³º¦Û¤v¤w¤£¬O¤p¯d¾Ç¥ÍÃhµÛ¦n©_»P¤£ª¾·Tªº½Ä«l¥h²`³y¨D¾Ç¡A¤]¤£¬O°Ñ¥[®È¦æ¹Î©Î¦Û¥Ñ¦æ¦í¶i¤¬P¯Å¤j¶º©±¡A³p»»¦Û¦bªº½à´º½ñ«C¡A¦Ó¬O¥¼¨Ó¤@¦~¤º¦b²§¦a¿W³Bªº¶iץͲP¡AIµÛ°l¨D·sª¾»P·s§Þ³Nªº¨Ï©R¡C¦b³o«Ê³¬ªº©Ð¶¡¤¤¡An¾Ç²ßªº¬O¥Í¬¡¡An¹ê¦æªº¬O¤Ï¬Ù¡C Áö¨S¦³®É®tªº§xÂZ¡AµM¦Ó«äºü©|¥¼¨H¾ýˤ£¯à»´©ö¤J¯v¡CÁö¬O²±®L¡A©]±ß«h¨G²DµS¦p¥xÆWªº²`¬î¡C±Àµ¡¦V¥~ÀôÅU¶g¾D¡AµL¼ô±xªºÀOi¿O°{Ã{¡A¤]¨S¦³©I¼Sªº¾÷¨®¤ÞÀºÁn¡A¥u¦³®A®AÂÎÁn¤Î¸s¸¿°g±¦©ó©ü¶À¸ô¿Oªº¸I¼²Án¡Cì¥H¬°³Á·í³Ò©Î«K§Q°Ó©±À³¥|³B¥i´M¡A¼öª¯¡Bº~³ùÁ`¥iªG¸¡¡A¨S·Q¨ìn¶R¦YªºªF¦èÁÙn¹B®ð»P®É¾÷¡AÀ\ÆU¨Ã«D³B³B¥i±o¡A©±®a¤]¦¦¥´¨Ë¡C¥u±o¥ô¥ÑÄȸzñFñFÁn¦A¦ñ¦X©]±ßªºÁnµ¨Ó¬q¤p©]¦±¡C ·í¤[¤F³Q¨þÅ@ºD¤Î³Q¦£¸Lªº¤u§@À£±oµL·v¤Ï¬ÙªºÂå¥Í¡AÃø±o¯à¦³¾÷·|§NÀR¡C¶Â©]ùØ¡A¤@¹õ¹õ»X¤Ó©_ªº¼v¹³§óÂA©úªº¬y¹L²´«e¡C¦Ç¦â¬O¤ÑªÅ°ß¤@ªºÃC¦â¡AÃú®ðÄjº©ªº³£¥«¦p^¤å¯ëÅý¤HºN¤£µÛÀYºü¡AµLªk¾A¤Áªºªí¹F¨ä¯u¥¿ªº®e»ª¡A³s¯ºÁn³£·|§N¾®ªº®ðÔ¹ï¤@ӨӦۨȼö±aªº¤HÁ`¬O¥Rº¡t±ªºÁr´ú¡C·Q¹³¦Û¤v±N¦b¤U³·¥B³±§Nªº^°ê¥V¤é¿W¦Û¤@¤H¦b³o¤pªÅ¶¡¤¤¡A¹LµÛ©t»÷¦Ó¹çÀRªº¥Í¬¡¡A¦Õ¯`ÅT°_³ìªv·Å´µ¹yªº·s¥@¬ö¿ûµ^Án¡A¤f°ã·Å¼öªº©@°Ø¡A¤£¹L¥¼ª¾«h¦h©ó®öº©¡CÂå¥ÍÁ`³Q¼ÐÅÒ¬°°ª¶Qªº¦æ·~¡A¹LµÛª÷¦r¶ð³»¯Åªº¥Í¬¡¡C¤H¨Ó¤H©¹ªºÂå°|¤¤¤Ö¤@¦ì©Î¦h¤@¦ìÂå®v¨ä¹êµL¶Ë¤j¶®¡A¤j®aªº¸}¨B¨ÌµM«æ«P¡A¯fµß«hÀH®É¦ø¾÷¦Ó°Ê¡A·Qn¤Ï§ðªø¤[¥H¨Ó©~©ó¦H¶Õªº¦a¦ì¡CµJ«æªº¶ý¶ý©êµÛµo¿N«y¹Âªº¤pªB¤Íµ¥«ÝµÛ´X¤ÀÄÁªº¬Ý¶Eªº®É¶¡¡A¥un¬Ý¤FÂå¥Í«K¦w¤ßªº»âÃĦ^®a¡Aªü·A«h¦b²M²z¤pªB¤Í¹Ã¦RªºÂ©ª«¡Cª¢¼öªº¥xÆW¨Ì¬O¦³¤H±¡¾aÃö«Yªº¤p®q¡A¸ôÃäÅu¿Ë¤Áªº©Û©I¬O¹C¤l³Ì·Å·xªº¨É¨ü¡Fµó¨¤ªº¦Ñ¼Ú¤Ú®á©ìµÛ§Fܼªº¨Å餴¦uµÛ¤éÁͨS¸¨ªº¥Ì¥J©±¡Aº¡¨¬¤p«Ä¥Î¤@¤¸¨â¤¸¶R¨ÓªºÅå³ß¡F®aªù«e¶À©ü¥«³õªºµæ³c¤£Á×·«Bªº¬°¥Í¬¡¥´«÷¡A±Ã±oªº¬OÃÇÀY¤p§Q¡FÁöµM³o¨Ç¤p¤Hª«¾Ç¾ú¤@©w¤£°ª¡A¦çµÛ¥¼¥²¥úÂA¡A³\¦h¤H§ó§Æ±æ®â°ö¤U¤@¥N¦¨¬°Âå¥Í¡A¥X¤HÀY¦a¡AµM¦Ó¥LÌ¥»¨¤£ª¾¤£Ä±µo´²¥Xªº¥Í©R¤¸¯À§ó³Ó¥P¤¦§®ÃÄÅý¤H¦³¥Í¦sªºì°Ê¤O¡C²³æªº¥Í¬¡¯à¦w³h¼Ö¹D¡AÂå¥Í¨Ã¤£¤@©wn¦³°ª¯Åªº¨É¨ü¤~²Å¦X¨¤À¡C±q«eªº¥xÆW¤H¯à¦bª«½è³h¥Fªº§x¹Ò¤¤¥Í¦s¡A²{¦bªº§Ú¤]n¯à¦b²§¶m®«Ç¤¤¥Í¬¡¡A¾ÌÂǪº«K¬O®Äªk¤Î¾Ç²ß¤p¤Hª«¦p¯ó®Ú¯ëªº¥Í©R¤O¡A¹y®ÉÅåı¦Û¤vªº¯Ü®z¡A¤]·PÃh¦Û¤vªº©¯¹B¡C½ö¦b§É¤W¤~µo²{¤Ö¤F§É´Ö³Q¡C ²Ä¤G¤Ñ²M¦³º³Qµ¡¥~ªºÄXÄX¸s³¾§n¿ô¡A°¸¦³¨ä¥L«Ç¤Í¨«¹Lªº¸}¨BÁnÂIºó¡A¦pªG¨¬¤£¥X¤á¡A¨S¦³¤Hª¾¾å©Ð¶¡¤º¦³¨S¦³¤H¦s¦b¡C°£¤Fn¦V¶i׳æ¦ì³ø¨ì¤§¥~¡A§ón¹³³¥¥~¨D¥Í¯ë¥h±´¯Á¤Î¸Ñ¨M¹¦ç¦í¦æªº¥Í¬¡¥²»Ý°ÝÃD¡A¶}©l¥Í©R¤¤¥t¤@¶¥¬qªº¾úÀI¡C
¡@ ¡@ |
||||||
ªø©°¨àµ£Âå°|¨àµ£¹L±Ó®ð³Ý·Àã¬ì ¸°ê°¶Âå®v
¸¶V¤Ó¥¬v¦A¾î¸ó¸¨ÁF¤s«á¡A¸¾÷°¸¨¦b¸¹ºÙ¬O¥þ¬ü«e¤¤jªº¤¦¦ò°ê»Ú¾÷³õ¡C¤µ¦~AAAAI (American Academy of Allergy, Asthma and Immunology) 60¶g¦~ªº¦~·|«K¿ï¾Ü¦b¬ìù©Ô¦h¦{ªº¤s«°Á|¦æ¡C¾Ú»¡¤j·|¶}©l«e¤¦¦ò¤s«°¤´¬O¦B¤Ñ³·¦a¡A´N¦b¤j·|¶}©l·í¤é©ñ´¸¡A¥u¤£¹L¿n³·µS¦b¡Aªì¬K¤T¤ëÁcªá¤´¥¼¿ô¡C¥ÑGINA²Õ´¥D¾ÉªºInternational Conference on Pediatric Asthma©ó²Ä¤@¤Ñµn³õ¡A³oÓijÃD¤]§l¤Þ¤F¥@¬É¦U¦aªº±M®aÅ¥²³À½Ãz·|³õ¡C ®ð³Ý²±¦æ²v¦~¦~Ãk¤É¬Oȱo§ó²`¤Jªº±´°Q¡A¥þ¥@¬É¤]¬°®ð³Ýªá¶O¤F¬Û·í¦hªº¸g¶O¤Î¤H¤O¡C¤¤«n¬ü¬wªºÂå®v¤]´£¥X¥LÌÁ{§É¤WªºªvÀø®ð³Ýªº±¡§Î¡C¨Ò¦pªü®Ú§Ê¦]±M·~¹L±Ó±M¬ìÂå®v¯Ê¥F©Î®ð³Ý¤§ªvÀø¸gÅ礣¨¬¡A©¹©¹¤ÏÂЪº³Ý»ï¥H¬°¬O¤@¯ë·P«_¦Ó¥¼¯à¤Î¦±µ¨üªvÀø¡C©Ò¦³¤p¨à¬ìÂå®v¤]¦Õ¼ô¯à¸Ô¤F¸Ñ³Ý»ï¤£¤@©w¬O®ð³Ý¡A¤]´N¬O¦³³Ý»ïÁn¨Ã¤£»Ýn¥ß§Y¨Ï¥ÎÃþ©T¾J¡C¬Û¹ïªº¨Ï¥ÎÃþ©T¾JªvÀøÁٮɱ`¦³®ð³Ý¯gª¬®É¡A§ó»Ý¦Ò¼{¨ä¥L¯e¯fªº¥i¯à¡A¦pG¹¹D°f¬y¡AºC©Ê»óÄuª¢©Î¨ä¥L©I§l¹D¯e¯f¡A¦Ó«D¤@ª½¥[«ªvÀø®ð³ÝªºÃĪ«¡A³o¤]¬O¨C¦ì¨à¬ìÂå®vÂÔ°O©ó¤ßªº·Ç«h¡C®ð³Ý¯uªº¨º»ò¦h¡AÁÙ¬OÂå®v±N¯f¤H¼ÐÅÒ¬°®ð³Ý¨ÓªvÀø¡H¬Oȱo²`«ä ªº¡C
¤j³°ªº½Õ¬dÅã¥Ü³º¦³¤E¦¨¤Kªº®ð³Ý¤pªB¤Í¦X¨Ö¨Ï¥Î§Ü¥Í¯ÀªvÀø¡Aªñ¤C¦¨·|¨Ï¥Î¤¤ÃĪvÀø¡A¬Ý¨ì¼Æ¾Ú¥uı±o³Y²§¡AÁöµMªvÀø·Ç«h¤¤»¡©ú°£«D»óÄuª¢©Î¦X¨Ö²Óµß·P¬Vªº¥i¯à¤~»Ý¨Ï¥Î§Ü¥Í¯À¡A¦ý¬O¦U¦aªvÀø¤ô·Ç¤£¤@©Î³\¦]¦a¦Ó¨î©y¡A¦Ó¤j³°¤]¦Ûq¤@®M§ó²³æ¤À¯ÅªºªvÀø¼Ð·Ç¡CÁöµMÂå®v¤j¥iªí¥Ü¬O¿í´`·Ç«hªvÀø®ð³Ý¡A¤£¦Û¥~©ó¥@¬É¼é¬y¡AµM¦Ó¦b¥xÆW¹ê»Úªº±¡§Î¤S¬O¦p¦ó©O¡HªvÀøªº·Ç«hÁö¤w«Ø¥ß¡A¦ý¹ê»ÚÁ{§ÉÂå®v¬O§_³£·Ó·Ç«h¬I¦æ¡HµM¦Ó·Ç«h´N¾A¦X¥þ¥@¬É¨C¤@Ó¦a°Ï¡H³o¤£¬On¦³°ê»ÚÆ[¡A¸¨¹ê¥»¤g¤Æªº³¯µÄÀݽաA¦Ón«Ø¥ß©Î×¥¿·Ç«h¬On¦³¬ì¾Ç¹êÅçÃÒ¾Ú¤ä«ù¨Ó¨î©w¡C
¤£¥u¥xÆW¤H®`©È¡u¬ü°ê¥P¤¦¡v¡A§Y¨Ï¬O¥ý¶iªº¬ü°ê¤´¹ï§l¤J©ÊÃþ©T¾J¨Ï¥ÎªººÃ¼{¤´³y¦¨®£·W¡A§Y¨Ï³\¦h¬ì¾ÇÃÒ¾ÚÃÒ¹ê§l¤J©ÊÃþ©T¾J¨Ã¤£·|¼vÅT¨°ª¡A¦¨ªø¤Î°©½è±K«×¡C¦ý¬O¤j³¡¤À®aªø®Ú²`¸¦©T¤Î¤@ª¾¥b¸Ñ¤U±µ¨ü¤F³\¦h¥H³_¶Ç³_ªº¸ê°T¡A¤Ï¦Ó¨Ï®ð³ÝªºªvÀø¾D¹Jªýê¡A³o´N»Ýn¾a±M®a§ó¥Î¤ß¥h±Ð¨|¥Á²³¡C
¥HGINAªºÆ[ÂI¡A§Æ±æ¯àq¥X¤@®M©ñ½Ñ¥|®ü±µ¥i¦æªº·Ç«h¡A¥xÆW±µ¨üÂåÀø¸ê°T¤ÎÂåÃĪvÀøªº¶i¨B¨ä¹êºâ¬O¥ý¶iªº¡A¤ñ¤§¾l¸gÀÙ¸¨«áªº°ê®a§Ú̪º¤pªB¤Í¯àªá·¥¤Öªºªá¶O´N¯à±µ¨ü¥ý¶iªºªvÀø¡A¥u¥i±¤¤´¥¼¯à±Nªá¶O¤ÎªvÀø¦¨®Ä¹F¨ì³Ì¨Î¤§®Ä¯q¡C¤F¸Ñ¨ä¥L°ê®aªvÀø±¡§Î¥u·P¨ì¥xÆWªº®ð³ÝÂåÀø¨ä¹ê¦³¤@©wªº¤ô·Ç¡A·|ij¤¤¤Þ¥Î¥xÆW¨àµ£®ð³Ý²±¦æ²vªº¸ê®Æ¤´¬O¤Q¦h¦~«eªº¼Æ¾Ú¡A¥uªí¥Ü¥@¬É¹ï¥xÆWªº¤F¸ÑÁÙ¤Ó¤Ö¡A²¦³º¤´¦³¤@¸s±M®aºë^¤´ÀqÀq¦b¬°¥xÆW¨àµ£®ð³Ý§V¤O¡C
·sªº¹L±Ó§K¬Ì¾÷Âà³°Äò¶i¦æ¤¤¡A¤]³\¤@¤p¨BÆJªºµo²{«K¯à¸ÑÄÀ©Ò¦³ªº°²³]»PÃøÃD¡A¦¨¥\ªº¤j·|¤£¥u¬OµwÅ餽Ãöªº³]³Æ¡AÁ¿ÃDªº³]p¡AºtÁ¿ªÌªºª¾¦W«×¤]¶·¬Û¤¬°t¦X¡CÁöµM®È³~³Ò¹y¡A¦ý¬OÂ×´I¦ÓºëªöªººtÁ¿¦¤w±N¯h¾Î§Ñ«o¡A¥u©È¤Ö»â²¤¤F¤@¨Ç¤j®vªº·ªö¡C
·íÂå¥ÍÁÙ¦bª§½×®ð³Ýªº·sªvÀø·Ç«h¡A©ÎÃļtÁÙ¦b±Mª`·sÃÄ«~ªº¥þ²y¥«³õ¦û¦³²v®É¡AÁÙ¦³³\¦h¤¤ªF°ê®aªº¤pªB¤Í¤´¥Í¬¡¦b¾Ôª§ªº³±¼v¤¤¡C¥L̤£n®ð³Ý¡A¦ý¥LÌ¥i¯à¨S¦³¸gÀ٤䴩±µ¨ü·sªºªvÀø¡AµM¦Ó¥Ļ󷥤O©IÆ~¤£n¾Ôª§¡C·|¤¤·P©Êªº¨q¥X¤@±i¤¤ªF¤pªB¤Í¹ïµÛ¤ÆµÛªá±mªº¤p¤¡ÅS¥XÅå³Yªºªí±¡¡A¨Ã¤£¬O¤p¤¡¥¼¯à±aµ¹¥LÌÅw¼Ö¡A¦Ó¬O¥Ḻq¥¼¬Ý¹L©Ò¿×ªº¤p¤¡¡C¦Ó·í¬ü°êÁ`²Î¥¿·Q¬°®Â½Ã¥¿¸q¦Ó®v¥X¦³¦W®É¡A¦b·|¤¤ªº¤Ï¾Ô¤H¹D«Å¨¥Ä¹±o¤F§ó¦hªº´xÁn¡C
µù°O¡GInternational conference on pediatric asthma¥u¬O¾ãÓ·|ij´Á¶¡ªº¤@¤p¸`½Òµ{¡A©|¦³¦Ê³õ¥H¤W±q°ò¦¨ìÁ{§Éªº½Òµ{¡AÂ×´I§§Áï¤@¦p¼h¼hÅ|»Aªº¸¨ÁF¤s¯ß ¡@
¡@ |
||||||
Survey of the Clinical Practice of Physicians in the Management of Asthma in Taiwan Kuo-Wei Yeh M.D. 1, Li-Chi Chiang PhD.2, Sue-Hsien Chen. M.S.N.3, and Jing-Long Huang M.D.1
Published in Asia Pacific Journal of Allergy and Immunology 2006 ABSTRACT Asthma is a common problem with a prevalence rate increasing every year. However, not all asthmatic patients receive appropriate treatment, partly due to the disease entity or patients¡¦ compliance, and partly due to physicians¡¦ knowledge and disposition in terms of treatment. This study was designed to investigate the current status of asthma treatment among clinicians in different practice settings, particularly regarding the acceptance of and adherence to asthma treatment guidelines and asthma patient education. Questionnaires were distributed by randomized sampling to doctors throughout the entire country. The questionnaire had six parts, measuring the following: 1) the use of different kinds of medication in the treatment of asthma; 2) adherence to asthma treatment guidelines; 3) the use of inhaled corticosteroids as part of management; 4) the use of peak flow meters in monitoring asthma; 5) relative efficiency in treating asthma; and 6) the use of a referral system, from general practitioners to specialists. There were 531 respondents out of 1000 questionnaires distributed. The results revealed the following: 1) 20.2% of physicians use oral corticosteroids for maintenance therapy; 2) 31.8% of physicians do not follow asthma treatment guidelines; 3) 77.2% of physicians use inhaled corticosteroids for maintenance therapy (physicians in medical centers and regional hospitals use inhaled corticosteroids more frequently than private practitioners); 4) 51% of doctors do not use peak flow meters to monitor asthma symptoms because of prohibitive costs; 5) approximately 80% of clinicians have confidence in dealing with asthma problems; and 6) 29.2% of general practitioners do not refer patients to asthma specialists unless there is poor control or a need for further evaluation. Adherence to asthma treatment guidelines is poor, and such guidelines need to be popularized or simplified. There are still many discrepancies among doctors at different levels of hospitals. Re-education and review of asthma knowledge is necessary to keep clinical practitioners at the forefront of standard practice.
|
||||||
Allergens and Allergic Diseases in Children KUO-WEI YEH M.D. Publishe in Acta Paediatrica Taiwan 2006 ABSTRACT The prevalence of allergic diseases is increasing gradually. Exposure to allergens is one of the trigger factors for symptoms in sensitized individuals. House dust mites and cockroach are the two most common indoor aeroallergens in Taiwan. There are wide differences in the numbers in different locations and in different seasons of these allergens. Sensitization to food allergens is prominent in young infants and can predict further aeroallergen sensitization. However, whether early exposure to allergens might develop or prevent allergic diseases in later childhood requires further research. Up to the present, allergen avoidance has demonstrated no prominent clinical efficacy in the improvement of allergic symptoms, although it is able to reduce allergen load in the environment. In a clinical regard, allergen avoidance should still be included as a part of treatment plans and be well explained to patients.
Survey of asthma care in Taiwan: a comparison of asthma specialists and general practitioners Kuo-Wei Yeh; Sue-Hsien Chen; Li-Chi Chiang; Li-Chen Chen; and Jing-Long Huang
Published in Ann Allergy Asthma Immunol. 2006;96:593¡V599.
Background: Asthma is a common disease in Taiwan. The promotion of quality care for asthmatic patients should focus not only on new treatment remedies but also on patient adherence to treatment and a continuous education program integrated into treatment plans. One reason for patients¡¦ poor response to treatment is the lack of asthma knowledge on the part of physicians in terms of attitudes toward treatment. Objective: To investigate the current status of asthma treatment among asthma specialists and general practitioners and their relative acceptance of and adherence to treatment guidelines. Methods: One thousand questionnaires were distributed to physicians throughout Taiwan using a randomized sampling procedure. The questionnaire asked about the use of different kinds of medications, including inhaled corticosteroids, to treat asthma; adherence to asthma treatment guidelines; the use of a peak flow meter for monitoring asthma status; and self-efficacy in the treatment of asthma. Results: A total of 526 questionnaires were returned. Of these, 90.4% of specialists and 63.2% of general practitioners would follow the guidelines for patient care (P< .002). It was significant that 79.8% of specialists but only 41.9% of general practitioners would instruct patients to use a peak flow meter to monitor symptoms (P < .001). Asthma specialists also seemed to be significantly more competent than general practitioners regarding asthma knowledge, instruction of inhalation techniques, use of peak flow meters to monitor symptoms, and making an action plan. Conclusions: To minimize the knowledge gap between specialists and general practitioners regarding asthma treatment, recognized treatment guidelines need to be popularized or simplified. Furthermore, the continuing education of general practitioners in asthma knowledge and management skills is important.
¡@
¡@ |
||||||
¡@ | ||||||
¡@ | ||||||
¡@ |